Free CME from PeerView
Continuing Nursing Education (CNE) Activities
Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum
StartThis activity expired on February 26, 2025; credit is no longer available.
Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum
Media: Enduring Material
Activity Release Date: January 27, 2024
Activity Expiration Date: February 26, 2025
Time to Complete Activity: 90 minutes
Activity Description
Which treatment advances are making an impact for patients with bladder cancer? Approved and emerging therapeutic strategies that include immune checkpoint inhibitors, antibody–drug conjugates (ADCs) and other classes of agents are changing outcomes for patients with locally advanced or metastatic disease, while those with earlier-stage disease, including non-muscle invasive bladder cancer (NMIBC) or high-risk muscle-invasive bladder cancer (MIBC), are benefiting from bladder-sparing and perioperative approaches. Join PeerView and the Bladder Cancer Advocacy Network (BCAN) to learn how these treatment advances translate into practice, as clinical decision points are brought to life through discussion of real-world patient cases. Featuring a panel of experts, as well as resources and tools from BCAN, this activity offers learners practical guidance on incorporating the latest data on a variety of therapeutic strategies into the development of personalized treatment plans for patients throughout the disease continuum, creating team-based protocols for managing adverse events, and addressing inequities in diagnosis and treatment to increase access to state-of-the-art care for all patients.
Target Audience
This activity has been designed to meet the educational needs of oncologists, urologists, advanced practice clinicians, and other healthcare professionals involved in the management of bladder cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize current data on therapeutic strategies based on innovative drug delivery techniques, targeted agents, and modern immunotherapy regimens for the treatment of bladder cancer
- Integrate approved and emerging therapeutic approaches into personalized treatment plans for patients with various stages of bladder cancer, considering evidence, guidelines, and principles of team-based and patient-centered care
- Implement evidence- and team-based management protocols to address the suite of adverse events associated with bladder cancer therapies
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Matthew D. Galsky, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director of Genitourinary Medical Oncology
Co-Leader, Cancer Clinical Investigation Program
Associate Director for Translational Research
Tisch Cancer Institute
New York, New York
Matthew D. Galsky, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; Bicycle
Therapeutics; Bristol Myers Squibb; Curis, Inc.; Daiichi Sankyo, Inc.; EMD
Serono Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly;
Merck & Co., Inc.; Pfizer and Seagen Inc.
Grant/Research Support from Bristol Myers Squibb and Merck & Co.,
Inc.
Faculty/Planner
Shilpa Gupta, MD
Clinical Professor of Medicine
Cleveland Clinic Lerner College of Medicine of CWRU
Director, Genitourinary Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio
Shilpa Gupta, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Bristol Myers Squibb; EMD Serono Inc.;
Gilead Sciences, Inc.; Merck & Co., Inc.; Pfizer; and Seattle Genetics
(Seagen Inc.).
Grant/Research Support from Bristol Myers Squibb; EMD Serono Inc.;
Exelixis, Inc.; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Merck & Co.,
Inc.; Novartis Pharmaceuticals Corporation; Pfizer; QED Therapeutics, Inc.;
and Seattle Genetics (Seagen Inc.).
Speaker for Bristol Myers Squibb; Gilead Sciences, Inc.; and Seattle
Genetics (Seagen Inc.).
Faculty/Planner
Andrea Necchi, MD
Associate Professor, Vita-Salute San Raffaele University
Director of Genitourinary Medical Oncology, IRCCS San Raffaele Hospital
Milan, Italy
Andrea Necchi, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; AstraZeneca;
Bristol Myers Squibb; CatalYm; F. Hoffmann-La Roche Ltd; Gilead Sciences,
Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; and Seagen
Inc.
Grant/Research Support from Bristol Myers Squibb; Gilead
Sciences, Inc.; Janssen Pharmaceuticals, Inc.; and Merck & Co.,
Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through independent educational grants from AstraZeneca; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Merck & Co., Inc.; and Seagen and Astellas.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/26/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on February 26, 2025; credit is no longer available.
Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum
Media: Enduring Material
Activity Release Date: January 27, 2024
Activity Expiration Date: February 26, 2025
Time to Complete Activity: 90 minutes
Activity Description
Which treatment advances are making an impact for patients with bladder cancer? Approved and emerging therapeutic strategies that include immune checkpoint inhibitors, antibody–drug conjugates (ADCs) and other classes of agents are changing outcomes for patients with locally advanced or metastatic disease, while those with earlier-stage disease, including non-muscle invasive bladder cancer (NMIBC) or high-risk muscle-invasive bladder cancer (MIBC), are benefiting from bladder-sparing and perioperative approaches. Join PeerView and the Bladder Cancer Advocacy Network (BCAN) to learn how these treatment advances translate into practice, as clinical decision points are brought to life through discussion of real-world patient cases. Featuring a panel of experts, as well as resources and tools from BCAN, this activity offers learners practical guidance on incorporating the latest data on a variety of therapeutic strategies into the development of personalized treatment plans for patients throughout the disease continuum, creating team-based protocols for managing adverse events, and addressing inequities in diagnosis and treatment to increase access to state-of-the-art care for all patients.
Target Audience
This activity has been designed to meet the educational needs of oncologists, urologists, advanced practice clinicians, and other healthcare professionals involved in the management of bladder cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize current data on therapeutic strategies based on innovative drug delivery techniques, targeted agents, and modern immunotherapy regimens for the treatment of bladder cancer
- Integrate approved and emerging therapeutic approaches into personalized treatment plans for patients with various stages of bladder cancer, considering evidence, guidelines, and principles of team-based and patient-centered care
- Implement evidence- and team-based management protocols to address the suite of adverse events associated with bladder cancer therapies
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Matthew D. Galsky, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director of Genitourinary Medical Oncology
Co-Leader, Cancer Clinical Investigation Program
Associate Director for Translational Research
Tisch Cancer Institute
New York, New York
Matthew D. Galsky, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; Bicycle
Therapeutics; Bristol Myers Squibb; Curis, Inc.; Daiichi Sankyo, Inc.; EMD
Serono Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly;
Merck & Co., Inc.; Pfizer and Seagen Inc.
Grant/Research Support from Bristol Myers Squibb and Merck & Co.,
Inc.
Faculty/Planner
Shilpa Gupta, MD
Clinical Professor of Medicine
Cleveland Clinic Lerner College of Medicine of CWRU
Director, Genitourinary Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio
Shilpa Gupta, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Bristol Myers Squibb; EMD Serono Inc.;
Gilead Sciences, Inc.; Merck & Co., Inc.; Pfizer; and Seattle Genetics
(Seagen Inc.).
Grant/Research Support from Bristol Myers Squibb; EMD Serono Inc.;
Exelixis, Inc.; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Merck & Co.,
Inc.; Novartis Pharmaceuticals Corporation; Pfizer; QED Therapeutics, Inc.;
and Seattle Genetics (Seagen Inc.).
Speaker for Bristol Myers Squibb; Gilead Sciences, Inc.; and Seattle
Genetics (Seagen Inc.).
Faculty/Planner
Andrea Necchi, MD
Associate Professor, Vita-Salute San Raffaele University
Director of Genitourinary Medical Oncology, IRCCS San Raffaele Hospital
Milan, Italy
Andrea Necchi, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; AstraZeneca;
Bristol Myers Squibb; CatalYm; F. Hoffmann-La Roche Ltd; Gilead Sciences,
Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; and Seagen
Inc.
Grant/Research Support from Bristol Myers Squibb; Gilead
Sciences, Inc.; Janssen Pharmaceuticals, Inc.; and Merck & Co.,
Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through independent educational grants from AstraZeneca; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Merck & Co., Inc.; and Seagen and Astellas.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/26/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Synergizing for Success in HCC: Immunotherapy Advances and the Role of the Interventional Radiologist-Oncologist Collaboration Across the Disease Continuum
StartThis activity expired on February 26, 2025; credit is no longer available.
Synergizing for Success in HCC: Immunotherapy Advances and the Role of the Interventional Radiologist-Oncologist Collaboration Across the Disease Continuum
Media: Enduring Material
Activity Release Date: January 27, 2024
Activity Expiration Date: February 26, 2025
Time to Complete Activity: 45 minutes
Activity Description
Developments in treatment options for hepatocellular carcinoma (HCC),
namely immune-based strategies, have enhanced outcomes across the disease
continuum. To effectively integrate these modern regimens into practice,
close collaboration among interventional radiologists (IR), medical
oncologists, and the wider care team are critical. In this Clinical Consults
activity, the expert faculty panel discuss patient scenarios illustrating
real-world applications of current and emerging data and provide guidance on
topics such as selecting and sequencing treatment over the course of disease,
delivering personalized care when integrating immunotherapy platforms, and
anticipating and managing safety/toxicity considerations.
This activity unravels the latest data on innovative
immunotherapy and locoregional therapy combinations in intermediate-stage
disease and the transition to systemic therapy in advanced disease. Join
today to learn what the experts have to say for synergizing success in
HCC!
Target Audience
This activity has been designed to meet the educational needs of interventional radiologists, medical oncologists, advanced practice clinicians, and other healthcare professionals involved in the management of HCC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Discuss the latest safety/efficacy evidence and guideline recommendations supporting clinical applications of immunotherapy regimens for the management of early-, intermediate-, and advanced-stage HCC
- Formulate personalized treatment plans with immunotherapy platforms for the management of HCC based on current and emerging clinical evidence, guideline recommendations, and expert guidance
- Apply team-based strategies to address practical aspects of care when integrating immunotherapy platforms, including managing immune-related adverse events, dosing considerations, care coordination across specialties, and patient/caregiver education
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Lipika Goyal, MD, MPhil
Director of Gastrointestinal Oncology
Associate Professor of Medicine
Division of Oncology
Stanford School of Medicine
Palo Alto, California
Lipika Goyal, MD, MPhil, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Alentis Therapeutics AG;
Basilea Pharmaceutica; Black Diamond Therapeutics, Inc.; Blueprint Medicines
Corporation; Eisai Inc./H3Biomedicine; Exelixis, Inc.; Genentech, Inc.;
Incyte Corporation; Kinnate Biopharma Inc.; Merck & Co., Inc.; QED
Therapeutics; Relay Therapeutics; Servier Pharmaceuticals; Sirtex Medical
Ltd; Surface Oncology; Taiho Oncology, Inc.; and TransThera
Biosciences.
Data Safety Monitoring Board for AstraZeneca.
Co-Chair/Planner
Riad Salem, MD, MBA
Professor of Radiology, Medicine, and Surgery
Chief, Section of Vascular and Interventional Radiology
Vice-Chairman, Image-Guided Therapy
Department of Radiology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Riad Salem, MD, MBA, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AstraZeneca; Bard
Pharmaceuticals; Boston Scientific Corporation; Cook Medical; Eisai
Inc./Merck & Co., Inc.; and Genentech, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an independent educational grant from AstraZeneca.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 2/26/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on February 26, 2025; credit is no longer available.
Synergizing for Success in HCC: Immunotherapy Advances and the Role of the Interventional Radiologist-Oncologist Collaboration Across the Disease Continuum
Media: Enduring Material
Activity Release Date: January 27, 2024
Activity Expiration Date: February 26, 2025
Time to Complete Activity: 45 minutes
Activity Description
Developments in treatment options for hepatocellular carcinoma (HCC),
namely immune-based strategies, have enhanced outcomes across the disease
continuum. To effectively integrate these modern regimens into practice,
close collaboration among interventional radiologists (IR), medical
oncologists, and the wider care team are critical. In this Clinical Consults
activity, the expert faculty panel discuss patient scenarios illustrating
real-world applications of current and emerging data and provide guidance on
topics such as selecting and sequencing treatment over the course of disease,
delivering personalized care when integrating immunotherapy platforms, and
anticipating and managing safety/toxicity considerations.
This activity unravels the latest data on innovative
immunotherapy and locoregional therapy combinations in intermediate-stage
disease and the transition to systemic therapy in advanced disease. Join
today to learn what the experts have to say for synergizing success in
HCC!
Target Audience
This activity has been designed to meet the educational needs of interventional radiologists, medical oncologists, advanced practice clinicians, and other healthcare professionals involved in the management of HCC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Discuss the latest safety/efficacy evidence and guideline recommendations supporting clinical applications of immunotherapy regimens for the management of early-, intermediate-, and advanced-stage HCC
- Formulate personalized treatment plans with immunotherapy platforms for the management of HCC based on current and emerging clinical evidence, guideline recommendations, and expert guidance
- Apply team-based strategies to address practical aspects of care when integrating immunotherapy platforms, including managing immune-related adverse events, dosing considerations, care coordination across specialties, and patient/caregiver education
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Lipika Goyal, MD, MPhil
Director of Gastrointestinal Oncology
Associate Professor of Medicine
Division of Oncology
Stanford School of Medicine
Palo Alto, California
Lipika Goyal, MD, MPhil, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Alentis Therapeutics AG;
Basilea Pharmaceutica; Black Diamond Therapeutics, Inc.; Blueprint Medicines
Corporation; Eisai Inc./H3Biomedicine; Exelixis, Inc.; Genentech, Inc.;
Incyte Corporation; Kinnate Biopharma Inc.; Merck & Co., Inc.; QED
Therapeutics; Relay Therapeutics; Servier Pharmaceuticals; Sirtex Medical
Ltd; Surface Oncology; Taiho Oncology, Inc.; and TransThera
Biosciences.
Data Safety Monitoring Board for AstraZeneca.
Co-Chair/Planner
Riad Salem, MD, MBA
Professor of Radiology, Medicine, and Surgery
Chief, Section of Vascular and Interventional Radiology
Vice-Chairman, Image-Guided Therapy
Department of Radiology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Riad Salem, MD, MBA, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AstraZeneca; Bard
Pharmaceuticals; Boston Scientific Corporation; Cook Medical; Eisai
Inc./Merck & Co., Inc.; and Genentech, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an independent educational grant from AstraZeneca.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 2/26/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Advancing Personalized Care in RCC: Navigating Rapid Therapeutic Expansion and Sequencing Strategies
StartThis activity expired on February 25, 2025; credit is no longer available.
Advancing Personalized Care in RCC: Navigating Rapid Therapeutic Expansion and Sequencing Strategies
Media: Enduring Material
Activity Release Date: January 26, 2024
Activity Expiration Date: February 25, 2025
Time to Complete Activity: 90 minutes
Activity Description
The rapid expansion in the renal cell carcinoma (RCC) therapeutic
landscape has brought new hope for patients with kidney cancer along with
increasing opportunities for healthcare professionals to provide personalized
care across the disease spectrum. With FDA approvals of TKIs and immune
checkpoint inhibitors in various disease settings, frontline treatment
options include dual immunotherapy and IO plus TKI regimens, with some of
these combinations showing benefit in patients with non–clear cell RCC, a
population with limited clinical data and poor treatment outcomes. Critical
therapeutic options are emerging in the perioperative setting, and further
impact has been made in the refractory setting for patients who have been
heavily pretreated.
Join PeerView and the Kidney Cancer Research Alliance (KCCure)
for an activity that features expert insights on the latest clinical trial
and real-world evidence along with guidance on how to integrate scientific
advances into modern RCC practice. Learn strategies for selecting and
sequencing treatments, mitigating and managing adverse events, and
incorporating shared decision-making into comprehensive, team-based care.
Target Audience
This activity has been designed to meet the educational needs of oncologists, urologists, advanced practice clinicians, nurses, and other healthcare professionals involved in the management of RCC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Review evidence on treatment efficacy and safety of approved and emerging therapeutic options for patients with RCC across different disease stages and histologic subtypes
- Design individualized treatment plans based on current evidence, as well as patient-, disease-, and treatment-specific factors for patients with RCC
- Develop team-based approaches to anticipate, mitigate, and manage adverse events associated with treatments for patients with RCC to promote optimal adherence, outcomes, and quality of life
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Sumanta Kumar Pal, MD, FASCO
Professor, Department of Medical Oncology & Therapeutics
Research
Co-Director, Kidney Cancer Program
City of Hope Comprehensive Cancer Center
Duarte, California
Sumanta Kumar Pal, MD, FASCO, has a financial interest/relationship or
affiliation in the form of:
Grant/Research Support from Allogene Therapeutics;
CRISPR Therapeutics; Eisai Co., Ltd.; Exelixis, Inc.; Genentech, Inc./F.
Hoffmann-La Roche Ltd.; and Pfizer all paid to institution.
Faculty/Planner
Pedro C. Barata, MD, MSc, FACP
Co-Leader Genitourinary (GU) Disease Team
Director of GU Medical Oncology Research Program
University Hospitals Seidman Cancer Center
Associate Professor of Medicine
Case Western Reserve University
Case Comprehensive Cancer Center
Cleveland, Ohio
Pedro C. Barata, MD, MSc, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.;
AVEO Pharmaceuticals, Inc; Bristol Myers Squibb; Clovis Oncology; EMD Serono;
Eisai Co., Ltd.; Exelixis, Inc.; Ipsen Biopharmaceuticals, Inc.; Pfizer; and
Sanofi.
Grant/Research Support from EMD Serono and Exelixis,
Inc.
Speakers Bureau participant with Bayer Corporation;
Caris Life Sciences; Merck & Co., Inc.; and Sanofi.
Faculty/Planner
David F. McDermott, MD
Chief, Medical Oncology
Beth Israel Deaconess Medical Center
Leader, Dana-Farber Harvard Cancer Center Kidney Cancer
Program
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
David F. McDermott, MD, has no financial interests/relationships or affiliations in relation to this activity.
Faculty/Planner
Tian Zhang, MD, MHS
Associate Professor, Division of Hematology and Oncology
Department of Internal Medicine
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas
Tian Zhang, MD, MHS, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Aravive; AstraZeneca;
AVEO Pharmaceuticals, Inc.; Bayer Corporation; Bristol Myers Squibb; Caris
Life Sciences; Eisai Co., Ltd.; EMD Serono; Exelixis, Inc.; Gilead Sciences,
Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis
Pharmaceuticals Corporation; Pfizer; Sanofi; and Seagen Inc.
Grant/Research Support from ALX Oncology; Janssen
Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Pfizer; and Tempus.
Other Financial or Material Support for leadership or
fiduciary role in Kidney Cancer Association (KCA) Medical Steering Committee;
Kidney Cancer Research Alliance (KCCure) Scientific Advisory Board; and
National Cancer Institute (NCI) Steering Renal Task Force.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Kidney Cancer Research Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported through medical education grants from AVEO Pharmaceuticals, Inc., Bristol Myers Squibb, Eisai Inc., Exelixis, Inc., and Merck & Co., Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.5 contact hour(s) in the area of pharmacology.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/25/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC
credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on February 25, 2025; credit is no longer available.
Advancing Personalized Care in RCC: Navigating Rapid Therapeutic Expansion and Sequencing Strategies
Media: Enduring Material
Activity Release Date: January 26, 2024
Activity Expiration Date: February 25, 2025
Time to Complete Activity: 90 minutes
Activity Description
The rapid expansion in the renal cell carcinoma (RCC) therapeutic
landscape has brought new hope for patients with kidney cancer along with
increasing opportunities for healthcare professionals to provide personalized
care across the disease spectrum. With FDA approvals of TKIs and immune
checkpoint inhibitors in various disease settings, frontline treatment
options include dual immunotherapy and IO plus TKI regimens, with some of
these combinations showing benefit in patients with non–clear cell RCC, a
population with limited clinical data and poor treatment outcomes. Critical
therapeutic options are emerging in the perioperative setting, and further
impact has been made in the refractory setting for patients who have been
heavily pretreated.
Join PeerView and the Kidney Cancer Research Alliance (KCCure)
for an activity that features expert insights on the latest clinical trial
and real-world evidence along with guidance on how to integrate scientific
advances into modern RCC practice. Learn strategies for selecting and
sequencing treatments, mitigating and managing adverse events, and
incorporating shared decision-making into comprehensive, team-based care.
Target Audience
This activity has been designed to meet the educational needs of oncologists, urologists, advanced practice clinicians, nurses, and other healthcare professionals involved in the management of RCC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Review evidence on treatment efficacy and safety of approved and emerging therapeutic options for patients with RCC across different disease stages and histologic subtypes
- Design individualized treatment plans based on current evidence, as well as patient-, disease-, and treatment-specific factors for patients with RCC
- Develop team-based approaches to anticipate, mitigate, and manage adverse events associated with treatments for patients with RCC to promote optimal adherence, outcomes, and quality of life
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Sumanta Kumar Pal, MD, FASCO
Professor, Department of Medical Oncology & Therapeutics
Research
Co-Director, Kidney Cancer Program
City of Hope Comprehensive Cancer Center
Duarte, California
Sumanta Kumar Pal, MD, FASCO, has a financial interest/relationship or
affiliation in the form of:
Grant/Research Support from Allogene Therapeutics;
CRISPR Therapeutics; Eisai Co., Ltd.; Exelixis, Inc.; Genentech, Inc./F.
Hoffmann-La Roche Ltd.; and Pfizer all paid to institution.
Faculty/Planner
Pedro C. Barata, MD, MSc, FACP
Co-Leader Genitourinary (GU) Disease Team
Director of GU Medical Oncology Research Program
University Hospitals Seidman Cancer Center
Associate Professor of Medicine
Case Western Reserve University
Case Comprehensive Cancer Center
Cleveland, Ohio
Pedro C. Barata, MD, MSc, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.;
AVEO Pharmaceuticals, Inc; Bristol Myers Squibb; Clovis Oncology; EMD Serono;
Eisai Co., Ltd.; Exelixis, Inc.; Ipsen Biopharmaceuticals, Inc.; Pfizer; and
Sanofi.
Grant/Research Support from EMD Serono and Exelixis,
Inc.
Speakers Bureau participant with Bayer Corporation;
Caris Life Sciences; Merck & Co., Inc.; and Sanofi.
Faculty/Planner
David F. McDermott, MD
Chief, Medical Oncology
Beth Israel Deaconess Medical Center
Leader, Dana-Farber Harvard Cancer Center Kidney Cancer
Program
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
David F. McDermott, MD, has no financial interests/relationships or affiliations in relation to this activity.
Faculty/Planner
Tian Zhang, MD, MHS
Associate Professor, Division of Hematology and Oncology
Department of Internal Medicine
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas
Tian Zhang, MD, MHS, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Aravive; AstraZeneca;
AVEO Pharmaceuticals, Inc.; Bayer Corporation; Bristol Myers Squibb; Caris
Life Sciences; Eisai Co., Ltd.; EMD Serono; Exelixis, Inc.; Gilead Sciences,
Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis
Pharmaceuticals Corporation; Pfizer; Sanofi; and Seagen Inc.
Grant/Research Support from ALX Oncology; Janssen
Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Pfizer; and Tempus.
Other Financial or Material Support for leadership or
fiduciary role in Kidney Cancer Association (KCA) Medical Steering Committee;
Kidney Cancer Research Alliance (KCCure) Scientific Advisory Board; and
National Cancer Institute (NCI) Steering Renal Task Force.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Kidney Cancer Research Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported through medical education grants from AVEO Pharmaceuticals, Inc., Bristol Myers Squibb, Eisai Inc., Exelixis, Inc., and Merck & Co., Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.5 contact hour(s) in the area of pharmacology.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/25/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC
credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Empowering Changes and Revolutionizing Treatment and Equity in Breast Cancer: Unlocking the Potential of Adjuvant CDK4/6 Inhibitors to Reduce the Risk of Recurrence and Improve Outcomes for Diverse Patient Populations With HR+/HER2- Early Breast Cancer
StartThis activity expired on January 25, 2025; credit is no longer available.
Empowering Changes and Revolutionizing Treatment and Equity in Breast Cancer: Unlocking the Potential of Adjuvant CDK4/6 Inhibitors to Reduce the Risk of Recurrence and Improve Outcomes for Diverse Patient Populations With HR+/HER2- Early Breast Cancer
Media: Enduring Material
Activity Release Date: January 26, 2024
Activity Expiration Date: January 25, 2025
Time to Complete Activity: 60 minutes
Activity Description
In this activity, Dr. Aditya Bardia reviews the latest evidence for adjuvant CDK4/6 inhibitors in HR+/HER2- early breast cancer (EBC) and discusses how these agents can reduce the risk of recurrence and improve outcomes.
Target Audience
This activity has been designed to meet the educational needs of oncologists and other clinicians involved in the care of patients with HR+/HER- EBC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Formulate individualized treatment plans inclusive of adjuvant CDK4/6 inhibitors and ET for patients with HR+/HER2- EBC based on latest evidence and recommendations
- Develop a team-based plan for patients with EBC undergoing adjuvant systemic therapy to closely monitor them, diagnose and manage AEs, and achieve optimal treatment adherence and persistence
- Implement strategies to recognize and address disparities in breast cancer for diverse racial and ethnic groups, with a goal of eliminating barriers and ensuring optimal care for all patients, especially minority populations in community settings
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Aditya Bardia, MD, MPH, FASCO
Professor of Medicine
Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research)
Medical Oncology Division
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, California
Aditya Bardia, MD, MPH, FASCO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Daiichi Sankyo
Inc./AstraZeneca; Foundation Medicine, Inc.; Genentech, Inc.; Immunomedics,
Inc./Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis
Pharmaceuticals Corporation; Pfizer; Phillips Healthcare Corporation;
Radius Health, Inc.; and Sanofi.
Grant/Research Support from Daiichi Sankyo
Inc./AstraZeneca; Genentech, Inc.; Immunomedics, Inc./Gilead Sciences,
Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation;
Pfizer; Radius Health, Inc.; and Sanofi.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
The activity titled “Empowering Changes and Revolutionizing Treatment and Equity in Breast Cancer: Unlocking the Potential of Adjuvant CDK4/6 Inhibitors to Reduce the Risk of Recurrence and Improve Outcomes for Diverse Patient Populations With HR+/HER2- Early Breast Cancer” has been registered to offer 1.0 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 1/25/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC
credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CC/NCPD/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on January 25, 2025; credit is no longer available.
Empowering Changes and Revolutionizing Treatment and Equity in Breast Cancer: Unlocking the Potential of Adjuvant CDK4/6 Inhibitors to Reduce the Risk of Recurrence and Improve Outcomes for Diverse Patient Populations With HR+/HER2- Early Breast Cancer
Media: Enduring Material
Activity Release Date: January 26, 2024
Activity Expiration Date: January 25, 2025
Time to Complete Activity: 60 minutes
Activity Description
In this activity, Dr. Aditya Bardia reviews the latest evidence for adjuvant CDK4/6 inhibitors in HR+/HER2- early breast cancer (EBC) and discusses how these agents can reduce the risk of recurrence and improve outcomes.
Target Audience
This activity has been designed to meet the educational needs of oncologists and other clinicians involved in the care of patients with HR+/HER- EBC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Formulate individualized treatment plans inclusive of adjuvant CDK4/6 inhibitors and ET for patients with HR+/HER2- EBC based on latest evidence and recommendations
- Develop a team-based plan for patients with EBC undergoing adjuvant systemic therapy to closely monitor them, diagnose and manage AEs, and achieve optimal treatment adherence and persistence
- Implement strategies to recognize and address disparities in breast cancer for diverse racial and ethnic groups, with a goal of eliminating barriers and ensuring optimal care for all patients, especially minority populations in community settings
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Aditya Bardia, MD, MPH, FASCO
Professor of Medicine
Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research)
Medical Oncology Division
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, California
Aditya Bardia, MD, MPH, FASCO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Daiichi Sankyo
Inc./AstraZeneca; Foundation Medicine, Inc.; Genentech, Inc.; Immunomedics,
Inc./Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis
Pharmaceuticals Corporation; Pfizer; Phillips Healthcare Corporation;
Radius Health, Inc.; and Sanofi.
Grant/Research Support from Daiichi Sankyo
Inc./AstraZeneca; Genentech, Inc.; Immunomedics, Inc./Gilead Sciences,
Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation;
Pfizer; Radius Health, Inc.; and Sanofi.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
The activity titled “Empowering Changes and Revolutionizing Treatment and Equity in Breast Cancer: Unlocking the Potential of Adjuvant CDK4/6 Inhibitors to Reduce the Risk of Recurrence and Improve Outcomes for Diverse Patient Populations With HR+/HER2- Early Breast Cancer” has been registered to offer 1.0 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 1/25/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC
credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CC/NCPD/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies
StartThis activity expired on February 25, 2025; credit is no longer available.
Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies
Media: Enduring Material
Activity Release Date: January 26, 2024
Activity Expiration Date: February 25, 2025
Time to Complete Activity: 90 minutes
Activity Description
Are you up for the challenge of modern treatment of prostate cancer? As
the therapeutic landscape for localized and advanced prostate cancer has
expanded greatly within the past few years, care team clinicians have a
variety of options available or on the horizon for use in personalized care
across the disease continuum. Approvals and positive results for high-risk
biochemically recurrent localized disease and treatment intensification
strategies for advanced disease with various regimens that include
AR-targeting agents, PARP inhibitors, modern radioligands, CDK4/6 inhibitors,
and IO + TKI combinations are set to further improve patient care.
Join PeerView and ZERO Prostate Cancer for a lively activity that includes
friendly competition among a panel of experts that competes to answer
questions on prostate cancer treatment while providing insight on evidence
supporting the use of a variety of prostate cancer therapeutics and
strategies for personalized treatment selection, including genetic and
molecular testing, and increasing access to optimal care.
Target Audience
This activity has been designed to meet the educational needs of urologic and medical oncologists, urologists, advanced practice clinicians, and other healthcare professionals involved in the management of prostate cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the rationale and clinical data supporting contemporary treatment options, including the need for germline and somatic testing, that can inform personalized treatment selection for patients with prostate cancer
- Design personalized team-based treatment protocols that incorporate key evidence-based strategies pertaining to approved and emerging therapeutics for patients with prostate cancer, including in the context of a clinical trial
- Manage treatment-related adverse events from personalized treatment plans for patients with prostate cancer to promote optimal adherence, outcomes, and quality of life
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Robert Dreicer, MD, MS, MACP, FASCO
Section Head Medical Oncology
Deputy Director, University of Virginia Comprehensive Cancer Center
Associate Director for Clinical Research
Co-Director, Paul Mellon Urologic Cancer Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia
Robert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; Bayer
Corporation; Exelixis, Inc.; Gilead Sciences, Inc.; Hinova; Janssen
Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; Sanofi Genzyme; Seagen
Inc.; and Tavanta Therapeutics.
Faculty/Planner
Alicia K. Morgans, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Director, Survivorship Program
Dana-Farber Cancer Institute
Boston, Massachusetts
Alicia K. Morgans, MD, MPH, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Advanced Accelerator Applications
(AAA); Antev Ltd.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation;
Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.;
Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix
Pharmaceuticals Limited.
Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation;
Myovant Sciences Ltd.; Pfizer; and Sanofi.
Faculty/Planner
Neal D. Shore, MD, FACS
Medical Director, Carolina Urologic Research Center
Myrtle Beach, South Carolina
Neal D. Shore, MD, FACS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa
Therapeutics; Amgen Inc.; Antev Ltd.; Arquer Diagnostics; Asieris
Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aura Biosciences, Inc.;
Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol
Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Cold Genesys Inc;
Dendreon Pharmaceuticals LLC; Exact Imaging; F. Hoffmann-La Roche
Ltd./Genentech, Inc.; Ferring Pharmaceuticals; FIZE Medical; Foundation
Medicine, Inc.; GenesisCare; ImmunityBio, Inc.; Incyte Corporation; Invitae
Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck &
Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd.; Myriad Genetics,
Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox
Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.;
Pfizer; Photocure; PlatformQ; PreView Medical, Inc.; ProFound Medical;
Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi
Genzyme; Specialty Networks; Telix Pharmaceuticals Limited; Tolmar
Pharmaceuticals, Inc.; and UroGen Pharma, Inc.
Faculty/Planner
Matthew R. Smith, MD, PhD
Claire and John Bertucci Endowed Chair in Genitourinary Cancers
Professor of Medicine, Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Matthew R. Smith, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Ambrx; Astellas Pharma Inc.; Bayer
Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported by medical education grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Exelixis, Inc., Lantheus Medical Imaging, and Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/25/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on February 25, 2025; credit is no longer available.
Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies
Media: Enduring Material
Activity Release Date: January 26, 2024
Activity Expiration Date: February 25, 2025
Time to Complete Activity: 90 minutes
Activity Description
Are you up for the challenge of modern treatment of prostate cancer? As
the therapeutic landscape for localized and advanced prostate cancer has
expanded greatly within the past few years, care team clinicians have a
variety of options available or on the horizon for use in personalized care
across the disease continuum. Approvals and positive results for high-risk
biochemically recurrent localized disease and treatment intensification
strategies for advanced disease with various regimens that include
AR-targeting agents, PARP inhibitors, modern radioligands, CDK4/6 inhibitors,
and IO + TKI combinations are set to further improve patient care.
Join PeerView and ZERO Prostate Cancer for a lively activity that includes
friendly competition among a panel of experts that competes to answer
questions on prostate cancer treatment while providing insight on evidence
supporting the use of a variety of prostate cancer therapeutics and
strategies for personalized treatment selection, including genetic and
molecular testing, and increasing access to optimal care.
Target Audience
This activity has been designed to meet the educational needs of urologic and medical oncologists, urologists, advanced practice clinicians, and other healthcare professionals involved in the management of prostate cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the rationale and clinical data supporting contemporary treatment options, including the need for germline and somatic testing, that can inform personalized treatment selection for patients with prostate cancer
- Design personalized team-based treatment protocols that incorporate key evidence-based strategies pertaining to approved and emerging therapeutics for patients with prostate cancer, including in the context of a clinical trial
- Manage treatment-related adverse events from personalized treatment plans for patients with prostate cancer to promote optimal adherence, outcomes, and quality of life
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Robert Dreicer, MD, MS, MACP, FASCO
Section Head Medical Oncology
Deputy Director, University of Virginia Comprehensive Cancer Center
Associate Director for Clinical Research
Co-Director, Paul Mellon Urologic Cancer Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia
Robert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; Bayer
Corporation; Exelixis, Inc.; Gilead Sciences, Inc.; Hinova; Janssen
Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; Sanofi Genzyme; Seagen
Inc.; and Tavanta Therapeutics.
Faculty/Planner
Alicia K. Morgans, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Director, Survivorship Program
Dana-Farber Cancer Institute
Boston, Massachusetts
Alicia K. Morgans, MD, MPH, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Advanced Accelerator Applications
(AAA); Antev Ltd.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation;
Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.;
Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix
Pharmaceuticals Limited.
Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation;
Myovant Sciences Ltd.; Pfizer; and Sanofi.
Faculty/Planner
Neal D. Shore, MD, FACS
Medical Director, Carolina Urologic Research Center
Myrtle Beach, South Carolina
Neal D. Shore, MD, FACS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa
Therapeutics; Amgen Inc.; Antev Ltd.; Arquer Diagnostics; Asieris
Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aura Biosciences, Inc.;
Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol
Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Cold Genesys Inc;
Dendreon Pharmaceuticals LLC; Exact Imaging; F. Hoffmann-La Roche
Ltd./Genentech, Inc.; Ferring Pharmaceuticals; FIZE Medical; Foundation
Medicine, Inc.; GenesisCare; ImmunityBio, Inc.; Incyte Corporation; Invitae
Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck &
Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd.; Myriad Genetics,
Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox
Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.;
Pfizer; Photocure; PlatformQ; PreView Medical, Inc.; ProFound Medical;
Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi
Genzyme; Specialty Networks; Telix Pharmaceuticals Limited; Tolmar
Pharmaceuticals, Inc.; and UroGen Pharma, Inc.
Faculty/Planner
Matthew R. Smith, MD, PhD
Claire and John Bertucci Endowed Chair in Genitourinary Cancers
Professor of Medicine, Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Matthew R. Smith, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Ambrx; Astellas Pharma Inc.; Bayer
Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported by medical education grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Exelixis, Inc., Lantheus Medical Imaging, and Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/25/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes
StartThis activity expired on January 21, 2025; credit is no longer available.
Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes
Media: Enduring Material
Activity Release Date: January 22, 2024
Activity Expiration Date: January 21, 2025
Time to Complete Activity: 60 minutes
Activity Description
Hypertrophic cardiomyopathy (HCM) occurs with an estimated prevalence of
as many as 1 in 200 people, with a mortality rate about 3 times greater
compared with individuals of a similar age without HCM. The clinical course
of HCM can vary greatly depending upon the individual, with some patients
being asymptomatic and others experiencing extreme fatigue, dyspnea, chest
pain, arrhythmias, and stroke. Experiencing symptoms is the most common
reason patients first seek care, but less than half of symptomatic HCM
patients initially seek care from a cardiologist.
In this learning opportunity, a cardiology expert and a primary care expert
sit down to discuss how primary care professionals can participate in the
diagnosis and management of HCM. By the end, learners will have increased
their ability to recognize symptoms of and risk factors for HCM and their
knowledge of screening tools for patients suspected of having HCM. Learners
will also better understand how to manage common comorbidities and how to
participate in follow-up care and monitoring of patients diagnosed with
HCM.
Target Audience
This activity has been designed to meet the educational needs of primary care clinicians including family medicine and internal medicine physicians, advanced practice clinicians, nurses, and other clinicians involved in the care of patients with or at risk for hypertrophic cardiomyopathy (HCM).
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Recognize symptoms and aspects of family history that may indicate risk for HCM or require differential diagnosis through further evaluation or screening
- Evaluate patients suspected of having HCM using tools such as ECG and echocardiography, including referral to specialty care, as appropriate
- Manage the comorbidities commonly associated with HCM (eg, atrial fibrillation, obesity, sleep apnea, and hypertension) in a shared-care model with specialty care providers
- Participate in follow-up care and monitoring of patients diagnosed with HCM, including checking for drug–drug interactions to ensure timely and safe treatment
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Anjali Tiku Owens, MD
Director, Center for Inherited Cardiovascular Disease
Section of Heart Failure
Transplantation and Mechanical Circulatory Support
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania
Anjali Tiku Owens, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for BioMarin; Bristol Myers Squibb;
Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer;
Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.
Grant/Research Support from Bristol Myers Squibb.
Faculty/Planner
Neil Skolnik, MD
Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Associate Director
Family Medicine Residency Program
Jefferson Health - Abington
Abington, Pennsylvania
Neil Skolnik, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Abbott; Astellas Pharma Inc.;
AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.;
Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk;
Sanofi; and Teva Pharmaceuticals USA, Inc.
Grant/Research Support from AstraZeneca; GSK; and Novo
Nordisk.
Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation;
Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and
Teva Pharmaceuticals USA, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 1/21/2025. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on January 21, 2025; credit is no longer available.
Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes
Media: Enduring Material
Activity Release Date: January 22, 2024
Activity Expiration Date: January 21, 2025
Time to Complete Activity: 60 minutes
Activity Description
Hypertrophic cardiomyopathy (HCM) occurs with an estimated prevalence of
as many as 1 in 200 people, with a mortality rate about 3 times greater
compared with individuals of a similar age without HCM. The clinical course
of HCM can vary greatly depending upon the individual, with some patients
being asymptomatic and others experiencing extreme fatigue, dyspnea, chest
pain, arrhythmias, and stroke. Experiencing symptoms is the most common
reason patients first seek care, but less than half of symptomatic HCM
patients initially seek care from a cardiologist.
In this learning opportunity, a cardiology expert and a primary care expert
sit down to discuss how primary care professionals can participate in the
diagnosis and management of HCM. By the end, learners will have increased
their ability to recognize symptoms of and risk factors for HCM and their
knowledge of screening tools for patients suspected of having HCM. Learners
will also better understand how to manage common comorbidities and how to
participate in follow-up care and monitoring of patients diagnosed with
HCM.
Target Audience
This activity has been designed to meet the educational needs of primary care clinicians including family medicine and internal medicine physicians, advanced practice clinicians, nurses, and other clinicians involved in the care of patients with or at risk for hypertrophic cardiomyopathy (HCM).
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Recognize symptoms and aspects of family history that may indicate risk for HCM or require differential diagnosis through further evaluation or screening
- Evaluate patients suspected of having HCM using tools such as ECG and echocardiography, including referral to specialty care, as appropriate
- Manage the comorbidities commonly associated with HCM (eg, atrial fibrillation, obesity, sleep apnea, and hypertension) in a shared-care model with specialty care providers
- Participate in follow-up care and monitoring of patients diagnosed with HCM, including checking for drug–drug interactions to ensure timely and safe treatment
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Anjali Tiku Owens, MD
Director, Center for Inherited Cardiovascular Disease
Section of Heart Failure
Transplantation and Mechanical Circulatory Support
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania
Anjali Tiku Owens, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for BioMarin; Bristol Myers Squibb;
Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer;
Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.
Grant/Research Support from Bristol Myers Squibb.
Faculty/Planner
Neil Skolnik, MD
Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Associate Director
Family Medicine Residency Program
Jefferson Health - Abington
Abington, Pennsylvania
Neil Skolnik, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Abbott; Astellas Pharma Inc.;
AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.;
Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk;
Sanofi; and Teva Pharmaceuticals USA, Inc.
Grant/Research Support from AstraZeneca; GSK; and Novo
Nordisk.
Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation;
Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and
Teva Pharmaceuticals USA, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 1/21/2025. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted Approaches
StartThis activity expired on February 18, 2025; credit is no longer available.
Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted Approaches
Media: Enduring Material
Activity Release Date: January 19, 2024
Activity Expiration Date: February 18, 2025
Time to Complete Activity: 90 minutes
Activity Description
As immunotherapy and targeted platforms transform hepatocellular carcinoma
(HCC) management, it is becoming increasingly important for oncologists to
“calibrate care” across all stages of disease. A recent wave of approved
therapeutic regimens, including immunotherapy/anti-VEGF combinations (eg,
atezolizumab and bevacizumab), dual immunotherapy combinations (ie,
durvalumab-tremelimumab), and next-generation TKIs (ie, lenvatinib) has been
introduced in the upfront setting. Recent additions to the second-line
setting have delivered improved options for patients with HCC including
multikinase inhibitors (ie, cabozantinib and regorafenib) and immune
checkpoint inhibitors (eg, pembrolizumab and nivolumab). Furthermore,
emerging data on other up-and-coming targeted platforms have shown the
benefit of combining immunotherapy with LRT for BCLC B disease and the
utility of adjuvant immunotherapy in resectable disease.
In collaboration with Blue Faery: The Adrienne Wilson Liver
Cancer Association, this MasterClass & Case Forum event will consist of a
series of concise, foundational lectures that support the utilization of
modern targeted and immunotherapy regimens across all stages of HCC. Each
MasterClass lecture segment will lead into a Case Forum discussion anchored
by real-world cases informed by the evidence. Learn the latest data on
important topics such as multimodal approaches in intermediate-stage HCC,
emerging adjuvant strategies in early-stage HCC, and adverse event
management.
Target Audience
This activity has been designed to meet the educational needs of gastrointestinal oncologists, medical oncologists, and advanced practice clinicians involved in the management of HCC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite current and emerging clinical evidence supporting the integration of immunotherapy and targeted platforms for the management of HCC
- Apply the latest safety/efficacy evidence supporting immunotherapy and targeted agents when developing personalized treatment plans for patients with HCC across all stages of disease
- Leverage the wider GI-oncology care team to address practical aspects of care when integrating modern therapeutic approaches, including patient consultation and treatment-related adverse event management
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Ghassan Abou-Alfa, MD, MBA
New York, New York
Professor
Memorial Sloan Kettering Cancer Center
Weill Cornell College at Cornell University
Trinity College Dublin
Ghassan Abou-Alfa, MD, MBA, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Autem
Therapeutics; Berry Genomics; BioNTech; Boehringer Ingelheim Pharmaceuticals,
Inc.; Bristol Myers Squibb; Eisai Inc.; Exelixis, Inc.; F. Hoffmann-La Roche
Ltd/Genentech, Inc.; Incyte; Ipsen Biopharmaceuticals, Inc.; Merck & Co.,
Inc.; Merus; Neogene Therapeutics; NewBridge Pharmaceuticals; Novartis
Pharmaceuticals Corporation; Servier Laboratories; Tempus; Vector; and
Yiviva.
Grant/Research Support from Agenus Inc.; Arcus
Biosciences, Inc.; AstraZeneca; BioNTech; Bristol Myers Squibb; Elicio
Therapeutics Inc; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Helsinn
Healthcare SA; Parker Institute for Cancer Immunotherapy; Pertzye; Puma
Biotechnology, Inc.; QED Therapeutics; and Yiviva.
Faculty/Planner
Anthony El-Khoueiry, MD
Associate Professor of Medicine
Associate Director for Clinical Research
Phase I Program Director
USC Norris Comprehensive Cancer Center
Los Angeles, California
Anthony El-Khoueiry, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Exelixis,
Inc.; F. Hoffmann-La Roche AG/Genentech, Inc.; Merck & Co., Inc.; Qurient;
and Senti Biosciences.
Grant/Research Support from Astex Pharmaceuticals;
AstraZeneca; Auransa Inc.; and Fulgent Pharma.
Faculty/Planner
Ahmed Omar Kaseb, MD, CMQ
John E. and Dorothy J. Harris Professorship in Gastrointestinal
Cancer Research
Member, National Hepatobiliary Task Force, NCI, USA
Tenured Professor and Director, Hepatocellular Carcinoma
Program
Director, MD Anderson HCC SPORE
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
Ahmed Omar Kaseb, MD, CMQ, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb;
Eisai Inc.; Exelixis, Inc.; Genentech, Inc.; Merck & Co., Inc.; and
Pfizer.
Grant/Research Support from Bristol Myers Squibb;
Eisai Inc.; Exelixis, Inc.; Genentech, Inc.; Merck & Co., Inc.; Pfizer; and
Tvardi Therapeutics.
Faculty/Planner
Stacey M. Stein, MD
Associate Professor of Medicine
Assistant Medical Director of the Clinical Trials Office
Leader, Hepatobiliary Program
Yale School of Medicine
New Haven, Connecticut
Stacey M. Stein, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AstraZeneca; Eisai Inc.;
Exelixis, Inc.; and Genentech, Inc.
Data Safety Monitoring Board for Aethlon Medical,
Inc.and Genentech, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Planner
Andrea Wilson Woods
President & Founder, Blue Faery
Andrea Wilson Woods has a financial interest/relationship or affiliation
in the form of:
Consultant for AstraZeneca and Humanise Health.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Blue Faery: The Adrienne Wilson Liver Cancer Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported through independent educational grants from AstraZeneca, Eisai Inc., Exelixis, Inc., Merck & Co., Inc., and Novocure, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/18/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on February 18, 2025; credit is no longer available.
Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted Approaches
Media: Enduring Material
Activity Release Date: January 19, 2024
Activity Expiration Date: February 18, 2025
Time to Complete Activity: 90 minutes
Activity Description
As immunotherapy and targeted platforms transform hepatocellular carcinoma
(HCC) management, it is becoming increasingly important for oncologists to
“calibrate care” across all stages of disease. A recent wave of approved
therapeutic regimens, including immunotherapy/anti-VEGF combinations (eg,
atezolizumab and bevacizumab), dual immunotherapy combinations (ie,
durvalumab-tremelimumab), and next-generation TKIs (ie, lenvatinib) has been
introduced in the upfront setting. Recent additions to the second-line
setting have delivered improved options for patients with HCC including
multikinase inhibitors (ie, cabozantinib and regorafenib) and immune
checkpoint inhibitors (eg, pembrolizumab and nivolumab). Furthermore,
emerging data on other up-and-coming targeted platforms have shown the
benefit of combining immunotherapy with LRT for BCLC B disease and the
utility of adjuvant immunotherapy in resectable disease.
In collaboration with Blue Faery: The Adrienne Wilson Liver
Cancer Association, this MasterClass & Case Forum event will consist of a
series of concise, foundational lectures that support the utilization of
modern targeted and immunotherapy regimens across all stages of HCC. Each
MasterClass lecture segment will lead into a Case Forum discussion anchored
by real-world cases informed by the evidence. Learn the latest data on
important topics such as multimodal approaches in intermediate-stage HCC,
emerging adjuvant strategies in early-stage HCC, and adverse event
management.
Target Audience
This activity has been designed to meet the educational needs of gastrointestinal oncologists, medical oncologists, and advanced practice clinicians involved in the management of HCC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite current and emerging clinical evidence supporting the integration of immunotherapy and targeted platforms for the management of HCC
- Apply the latest safety/efficacy evidence supporting immunotherapy and targeted agents when developing personalized treatment plans for patients with HCC across all stages of disease
- Leverage the wider GI-oncology care team to address practical aspects of care when integrating modern therapeutic approaches, including patient consultation and treatment-related adverse event management
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Ghassan Abou-Alfa, MD, MBA
New York, New York
Professor
Memorial Sloan Kettering Cancer Center
Weill Cornell College at Cornell University
Trinity College Dublin
Ghassan Abou-Alfa, MD, MBA, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Autem
Therapeutics; Berry Genomics; BioNTech; Boehringer Ingelheim Pharmaceuticals,
Inc.; Bristol Myers Squibb; Eisai Inc.; Exelixis, Inc.; F. Hoffmann-La Roche
Ltd/Genentech, Inc.; Incyte; Ipsen Biopharmaceuticals, Inc.; Merck & Co.,
Inc.; Merus; Neogene Therapeutics; NewBridge Pharmaceuticals; Novartis
Pharmaceuticals Corporation; Servier Laboratories; Tempus; Vector; and
Yiviva.
Grant/Research Support from Agenus Inc.; Arcus
Biosciences, Inc.; AstraZeneca; BioNTech; Bristol Myers Squibb; Elicio
Therapeutics Inc; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Helsinn
Healthcare SA; Parker Institute for Cancer Immunotherapy; Pertzye; Puma
Biotechnology, Inc.; QED Therapeutics; and Yiviva.
Faculty/Planner
Anthony El-Khoueiry, MD
Associate Professor of Medicine
Associate Director for Clinical Research
Phase I Program Director
USC Norris Comprehensive Cancer Center
Los Angeles, California
Anthony El-Khoueiry, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Exelixis,
Inc.; F. Hoffmann-La Roche AG/Genentech, Inc.; Merck & Co., Inc.; Qurient;
and Senti Biosciences.
Grant/Research Support from Astex Pharmaceuticals;
AstraZeneca; Auransa Inc.; and Fulgent Pharma.
Faculty/Planner
Ahmed Omar Kaseb, MD, CMQ
John E. and Dorothy J. Harris Professorship in Gastrointestinal
Cancer Research
Member, National Hepatobiliary Task Force, NCI, USA
Tenured Professor and Director, Hepatocellular Carcinoma
Program
Director, MD Anderson HCC SPORE
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
Ahmed Omar Kaseb, MD, CMQ, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb;
Eisai Inc.; Exelixis, Inc.; Genentech, Inc.; Merck & Co., Inc.; and
Pfizer.
Grant/Research Support from Bristol Myers Squibb;
Eisai Inc.; Exelixis, Inc.; Genentech, Inc.; Merck & Co., Inc.; Pfizer; and
Tvardi Therapeutics.
Faculty/Planner
Stacey M. Stein, MD
Associate Professor of Medicine
Assistant Medical Director of the Clinical Trials Office
Leader, Hepatobiliary Program
Yale School of Medicine
New Haven, Connecticut
Stacey M. Stein, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AstraZeneca; Eisai Inc.;
Exelixis, Inc.; and Genentech, Inc.
Data Safety Monitoring Board for Aethlon Medical,
Inc.and Genentech, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Planner
Andrea Wilson Woods
President & Founder, Blue Faery
Andrea Wilson Woods has a financial interest/relationship or affiliation
in the form of:
Consultant for AstraZeneca and Humanise Health.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Blue Faery: The Adrienne Wilson Liver Cancer Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported through independent educational grants from AstraZeneca, Eisai Inc., Exelixis, Inc., Merck & Co., Inc., and Novocure, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/18/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice
StartThis activity expired on February 18, 2025; credit is no longer available.
Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice
Media: Enduring Material
Activity Release Date: January 19, 2024
Activity Expiration Date: February 18, 2025
Time to Complete Activity: 90 minutes
Activity Description
Groundbreaking science in personalized therapeutic approaches for advanced
biliary tract cancers (BTCs) has resulted in the expansion of a diverse
management model, empowering oncologists to battle the disease, as emerging
evidence continues to reshape treatment planning based on patient-specific
findings. These developments have led to the approval of several immune-based
and molecularly targeted therapies for the clinical management of advanced
BTCs. Through a case-based discussion, experts will provide valuable insight
on the practical aspects of integrating these new and emerging therapeutic
platforms into your clinical practice.
This Seminars and Tumor Board activity, based on a recent live symposium and
produced in collaboration with the Cholangiocarcinoma Foundation (CCF), pairs
real-world case scenarios with the practice-changing evidence that guides
treatment selection for the management of advanced BTCs. PeerView’s
collaboration with the CCF includes their educational resources and patient
stories to improve patient education, engagement in care, and shared
decision-making.
Target Audience
This activity has been designed to meet the educational needs of oncologists, gastroenterologists, advanced practice clinicians (NPs/PAs), and other relevant healthcare professionals involved in the management of biliary cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the latest clinical evidence supporting the use of modern and emerging therapeutic approaches, including immunotherapy and targeted platforms, for the management of BTC
- Utilize biomarker findings, current evidence, and guideline recommendations to build individualized treatment regimens for patients with advanced BTC
- Develop team-based strategies to address practical considerations of care, including patient education and AE management
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Milind Javle, MD
Professor, Department of Gastrointestinal (GI) Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Milind Javle, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.;
Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation;
BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.;
GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen;
Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis
Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.;
Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co.
Ltd.
Faculty/Planner
Tanios Bekaii-Saab, MD
Professor, Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer, Mayo Clinic Cancer Center (All
Regions)
Consortium Chair, Academic and Community Cancer Research United (ACCRU)
Phoenix, Arizona
Tanios Bekaii-Saab, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for (to self) AbbVie; Artiva
Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines;
Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity
Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact
Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.;
GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.;
Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.;
Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio
Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.;
Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation;
Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer;
Seattle Genetics; and Servier Laboratories.
Grant/Research Support from AbGenomics Corporation; Agios
Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer
Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene
Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte
Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati
Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle
Genetics. Research funding to Institution.
Data Safety Monitoring Board for 1Globe Health Institute;
AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai
Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals,
Inc.; and The Valley Hospital.
Other Financial or Material Support from holding patents
WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to
Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
CACHEXIA – Licensed to Recursion.
Faculty/Planner
Rachna Shroff, MD, MS, FASCO
Chief, Division of Hematology/Oncology, UA COM-T
Associate Director of Clinical Investigations, UACC
Associate Dean, Clinical and Translational Research, UA COM-T
Professor of Medicine
University of Arizona Cancer Center (UACC)
University of Arizona College of Medicine – Tucson (UA COM-T)
Tucson, Arizona
Rachna Shroff, MD, MS, FASCO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim;
Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED
Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and
Zymeworks Inc.
Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis,
Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.;
NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael
Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/18/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on February 18, 2025; credit is no longer available.
Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice
Media: Enduring Material
Activity Release Date: January 19, 2024
Activity Expiration Date: February 18, 2025
Time to Complete Activity: 90 minutes
Activity Description
Groundbreaking science in personalized therapeutic approaches for advanced
biliary tract cancers (BTCs) has resulted in the expansion of a diverse
management model, empowering oncologists to battle the disease, as emerging
evidence continues to reshape treatment planning based on patient-specific
findings. These developments have led to the approval of several immune-based
and molecularly targeted therapies for the clinical management of advanced
BTCs. Through a case-based discussion, experts will provide valuable insight
on the practical aspects of integrating these new and emerging therapeutic
platforms into your clinical practice.
This Seminars and Tumor Board activity, based on a recent live symposium and
produced in collaboration with the Cholangiocarcinoma Foundation (CCF), pairs
real-world case scenarios with the practice-changing evidence that guides
treatment selection for the management of advanced BTCs. PeerView’s
collaboration with the CCF includes their educational resources and patient
stories to improve patient education, engagement in care, and shared
decision-making.
Target Audience
This activity has been designed to meet the educational needs of oncologists, gastroenterologists, advanced practice clinicians (NPs/PAs), and other relevant healthcare professionals involved in the management of biliary cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the latest clinical evidence supporting the use of modern and emerging therapeutic approaches, including immunotherapy and targeted platforms, for the management of BTC
- Utilize biomarker findings, current evidence, and guideline recommendations to build individualized treatment regimens for patients with advanced BTC
- Develop team-based strategies to address practical considerations of care, including patient education and AE management
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Milind Javle, MD
Professor, Department of Gastrointestinal (GI) Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Milind Javle, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.;
Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation;
BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.;
GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen;
Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis
Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.;
Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co.
Ltd.
Faculty/Planner
Tanios Bekaii-Saab, MD
Professor, Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer, Mayo Clinic Cancer Center (All
Regions)
Consortium Chair, Academic and Community Cancer Research United (ACCRU)
Phoenix, Arizona
Tanios Bekaii-Saab, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for (to self) AbbVie; Artiva
Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines;
Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity
Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact
Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.;
GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.;
Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.;
Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio
Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.;
Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation;
Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer;
Seattle Genetics; and Servier Laboratories.
Grant/Research Support from AbGenomics Corporation; Agios
Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer
Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene
Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte
Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati
Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle
Genetics. Research funding to Institution.
Data Safety Monitoring Board for 1Globe Health Institute;
AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai
Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals,
Inc.; and The Valley Hospital.
Other Financial or Material Support from holding patents
WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to
Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
CACHEXIA – Licensed to Recursion.
Faculty/Planner
Rachna Shroff, MD, MS, FASCO
Chief, Division of Hematology/Oncology, UA COM-T
Associate Director of Clinical Investigations, UACC
Associate Dean, Clinical and Translational Research, UA COM-T
Professor of Medicine
University of Arizona Cancer Center (UACC)
University of Arizona College of Medicine – Tucson (UA COM-T)
Tucson, Arizona
Rachna Shroff, MD, MS, FASCO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim;
Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED
Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and
Zymeworks Inc.
Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis,
Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.;
NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael
Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/18/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC
StartThis activity expired on February 17, 2025; credit is no longer available.
Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC
Media: Enduring Material
Activity Release Date: January 18, 2024
Activity Expiration Date: February 17, 2025
Time to Complete Activity: 60 minutes
Activity Description
Despite their established role in the treatment of HR+, HER2- metastatic
breast cancer (MBC) and accumulating evidence supporting their adjuvant use
in HR+, HER2- early breast cancer (EBC), questions still surround CDK4/6
inhibitors and their use. While these agents were historically thought to be
largely similar and interchangeable, evolving data from clinical and
translational studies have shown that CDK4/6 inhibitors are not the same.
They have key differences in their chemical, biologic, pharmacologic, and
clinical features and different toxicity profiles, despite all being orally
bioavailable. Therefore, we must re-evaluate how we approach CDK4/6
inhibitors and integrate them into individualized treatment plans for
patients throughout the disease continuum, as well as consider what that
looks like in the real-world setting and how to make the most of them and
their distinct properties in the frontline setting and beyond?
In this activity, based on a recent live virtual workshop, learners receive
an in-depth, expert assessment of CDK4/6 inhibitors in HR+, HER2- EBC and
MBC, which provides the foundation for case-based discussions and tool-based
demonstrations of algorithmic decision aids designed to guide risk
assessment, candidate selection for therapy, and the optimal delivery of
treatment to reduce the risk of recurrence in individuals with HR+, HER2- EBC
before transitioning to HR+, HER2- MBC to demonstrate patient evaluation,
identify factors for prognostication, and model treatment planning,
selection, and sequencing throughout the advance disease continuum.
Additionally, the panel shares strategies to mitigate and manage common
adverse reactions associated with CDK4/6 inhibitors to improve treatment
adherence and persistence.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with early and metastatic breast cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients with HR+, HER2- EBC and MBC via thorough assessment of clinical, pathologic, genomic, and other relevant factors
- Design individualized treatment protocols integrating CDK4/6 inhibitor therapy for patients with HR+, HER2- EBC and MBC based on the latest evidence, guidelines, and tumor/disease characteristics
- Develop team-based strategies to achieve optimal treatment adherence/persistence and prevention/mitigation of AEs associated with different CDK4/6 inhibitors in the treatment of HR+, HER2- EBC and MBC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Erika Hamilton, MD
Chair, Breast Executive Committee
Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee
Erika Hamilton, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas,
Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, Inc.;
Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich
LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly;
Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation;
Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity
Science (all paid to institution).
Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc;
Acerta Pharma; ADC Therapeutics SA; Akeso Biopharma Co., Ltd.; Amgen Inc.;
Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene,
Inc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou)
Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cascadian
Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis,
Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer
Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics;
eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD
Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM
Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.;
Harpoon Therapeutics; HUTCHMED (China) Limited; ImmunoGen, Inc.;
Immunomedics, Inc.; Incyte; Infinity Pharmaceuticals, Inc.; InvestisBio;
Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, Inc.; Karyopharm;
Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics,
Inc.; MedImmune, LLC; Mersana Therapeutics; Merus; Millennium
Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals
Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova
Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove Inc.; Pfizer;
PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr Immunotherapeutics;
Plexxikon; Radius Health, Inc.; Regeneron Pharmaceuticals Inc.; Relay
Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen Inc.; Sermonix
Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, Inc.;
Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; TapImmune Inc;
TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.;
Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics;
and Zymeworks Inc. (all paid to institution).
Faculty/Planner
Komal Jhaveri, MD, FACP
Patricia and James Cayne Chair for Junior Faculty
Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Memorial Sloan Kettering Cancer Center/Evelyn H. Lauder Breast and Imaging
Center
New York, New York
Komal Jhaveri, MD, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Blueprint
Medicines; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; Jounce Therapeutics, Inc.; Lilly/Loxo
Oncology; Menarini Group/Stemline Therapeutics; Novartis Pharmaceuticals
Corporation; Pfizer; Scorpion Therapeutics; Seattle Genetics, Inc. (Seagen
Inc.); Sun Pharma Advanced Research Company; and Taiho Oncology, Inc.
Grant/Research Support from ADC Therapeutics SA; AstraZeneca;
Blueprint Medicines; Debiopharm; Genentech, Inc.; Gilead Sciences, Inc.;
Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novita
Pharmaceuticals, Inc.; Pfizer; Puma Biotechnology, Inc.; Scorpion
Therapeutics; and Zymeworks Inc.
Faculty/Planner
Professor Stephen Johnston, MA, PhD
Professor of Breast Cancer Medicine & Head of Medical Oncology
Consultant Medical Oncologist & Head of The Breast Unit
The Royal Marsden NHS Foundation Trust & The Institute of Cancer
Research
Chelsea, London, United Kingdom
Professor Stephen Johnston, MA, PhD, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly; Novartis
Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; and
Sanofi.
Grant/Research Support from AstraZeneca; F. Hoffmann-La Roche
Ltd/Genentech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and
Puma Biotechnology, Inc.
Speakers Bureau participant with AstraZeneca; Eisai Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; and Pfizer.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-015-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/17/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on February 17, 2025; credit is no longer available.
Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC
Media: Enduring Material
Activity Release Date: January 18, 2024
Activity Expiration Date: February 17, 2025
Time to Complete Activity: 60 minutes
Activity Description
Despite their established role in the treatment of HR+, HER2- metastatic
breast cancer (MBC) and accumulating evidence supporting their adjuvant use
in HR+, HER2- early breast cancer (EBC), questions still surround CDK4/6
inhibitors and their use. While these agents were historically thought to be
largely similar and interchangeable, evolving data from clinical and
translational studies have shown that CDK4/6 inhibitors are not the same.
They have key differences in their chemical, biologic, pharmacologic, and
clinical features and different toxicity profiles, despite all being orally
bioavailable. Therefore, we must re-evaluate how we approach CDK4/6
inhibitors and integrate them into individualized treatment plans for
patients throughout the disease continuum, as well as consider what that
looks like in the real-world setting and how to make the most of them and
their distinct properties in the frontline setting and beyond?
In this activity, based on a recent live virtual workshop, learners receive
an in-depth, expert assessment of CDK4/6 inhibitors in HR+, HER2- EBC and
MBC, which provides the foundation for case-based discussions and tool-based
demonstrations of algorithmic decision aids designed to guide risk
assessment, candidate selection for therapy, and the optimal delivery of
treatment to reduce the risk of recurrence in individuals with HR+, HER2- EBC
before transitioning to HR+, HER2- MBC to demonstrate patient evaluation,
identify factors for prognostication, and model treatment planning,
selection, and sequencing throughout the advance disease continuum.
Additionally, the panel shares strategies to mitigate and manage common
adverse reactions associated with CDK4/6 inhibitors to improve treatment
adherence and persistence.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with early and metastatic breast cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients with HR+, HER2- EBC and MBC via thorough assessment of clinical, pathologic, genomic, and other relevant factors
- Design individualized treatment protocols integrating CDK4/6 inhibitor therapy for patients with HR+, HER2- EBC and MBC based on the latest evidence, guidelines, and tumor/disease characteristics
- Develop team-based strategies to achieve optimal treatment adherence/persistence and prevention/mitigation of AEs associated with different CDK4/6 inhibitors in the treatment of HR+, HER2- EBC and MBC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Erika Hamilton, MD
Chair, Breast Executive Committee
Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee
Erika Hamilton, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas,
Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, Inc.;
Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich
LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly;
Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation;
Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity
Science (all paid to institution).
Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc;
Acerta Pharma; ADC Therapeutics SA; Akeso Biopharma Co., Ltd.; Amgen Inc.;
Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene,
Inc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou)
Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cascadian
Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis,
Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer
Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics;
eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD
Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM
Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.;
Harpoon Therapeutics; HUTCHMED (China) Limited; ImmunoGen, Inc.;
Immunomedics, Inc.; Incyte; Infinity Pharmaceuticals, Inc.; InvestisBio;
Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, Inc.; Karyopharm;
Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics,
Inc.; MedImmune, LLC; Mersana Therapeutics; Merus; Millennium
Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals
Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova
Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove Inc.; Pfizer;
PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr Immunotherapeutics;
Plexxikon; Radius Health, Inc.; Regeneron Pharmaceuticals Inc.; Relay
Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen Inc.; Sermonix
Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, Inc.;
Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; TapImmune Inc;
TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.;
Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics;
and Zymeworks Inc. (all paid to institution).
Faculty/Planner
Komal Jhaveri, MD, FACP
Patricia and James Cayne Chair for Junior Faculty
Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Memorial Sloan Kettering Cancer Center/Evelyn H. Lauder Breast and Imaging
Center
New York, New York
Komal Jhaveri, MD, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Blueprint
Medicines; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; Jounce Therapeutics, Inc.; Lilly/Loxo
Oncology; Menarini Group/Stemline Therapeutics; Novartis Pharmaceuticals
Corporation; Pfizer; Scorpion Therapeutics; Seattle Genetics, Inc. (Seagen
Inc.); Sun Pharma Advanced Research Company; and Taiho Oncology, Inc.
Grant/Research Support from ADC Therapeutics SA; AstraZeneca;
Blueprint Medicines; Debiopharm; Genentech, Inc.; Gilead Sciences, Inc.;
Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novita
Pharmaceuticals, Inc.; Pfizer; Puma Biotechnology, Inc.; Scorpion
Therapeutics; and Zymeworks Inc.
Faculty/Planner
Professor Stephen Johnston, MA, PhD
Professor of Breast Cancer Medicine & Head of Medical Oncology
Consultant Medical Oncologist & Head of The Breast Unit
The Royal Marsden NHS Foundation Trust & The Institute of Cancer
Research
Chelsea, London, United Kingdom
Professor Stephen Johnston, MA, PhD, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly; Novartis
Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; and
Sanofi.
Grant/Research Support from AstraZeneca; F. Hoffmann-La Roche
Ltd/Genentech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and
Puma Biotechnology, Inc.
Speakers Bureau participant with AstraZeneca; Eisai Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; and Pfizer.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-015-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/17/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Adapting Our Strategies for Decision-Making in Testing and Treatment of RET-Altered Lung and Thyroid Cancers: A Personalized Learning Journey
StartThis activity expired on January 16, 2025; credit is no longer available.
Adapting Our Strategies for Decision-Making in Testing and Treatment of RET-Altered Lung and Thyroid Cancers: A Personalized Learning Journey
Media: Enduring Material
Activity Release Date: January 17, 2024
Activity Expiration Date: January 16, 2025
Time to Complete Activity: 60 minutes
Activity Description
RET alterations are the primary drivers of tumor growth in a
number of tumor types, with RET fusions relevant in NSCLC, papillary
thyroid cancer, and other solid tumors, and RET point mutations
relevant in sporadic and germline medullary thyroid cancer. Selective RET
inhibitors have become the standard-of-care options and transformed treatment
and subsequent outcomes in RET-altered lung and thyroid cancers.
Thus, upfront detection of RET status is essential in lung and
thyroid cancers to guide treatment decisions, underscoring the importance of
timely, methodologically appropriate, and comprehensive genomic
testing.
This customizable, question-based educational activity provides
evidence-based, expert-guided instruction on biomarker testing strategies,
interpretation of results, and selection of biomarker-driven precision
therapies for patients with advanced/metastatic RET-altered NSCLC
and thyroid cancers.
Target Audience
This activity has been designed to meet the educational needs of oncologists, pathologists, endocrinologists, pulmonologists, advanced practice providers, nurses, pharmacists, and other clinicians involved in the care of patients with lung and thyroid cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Apply best practices and guideline recommendations for biomarker testing for detection of RET alterations in NSCLC and TC
- Examine the evolving evidence supporting the use of RET inhibitors in NSCLC with RET fusions and TC with RET fusions or point mutations
- Integrate evidence-based, biomarker-guided targeted therapy with RET inhibitors into treatment plans for patients with RET-altered NSCLC and TC
- Foster team-based collaboration and shared decision-making to achieve optimal biomarker testing, treatment selection, and outcomes for patients with RET-altered NSCLC and TC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Professor Benjamin Solomon, MBBS, PhD, FRACP, FAHMS
Head Lung Medical Oncology Service
Peter MacCallum Cancer Centre
Melbourne, Australia
Professor Benjamin Solomon, MBBS, PhD, FRACP, FAHMS, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Bristol Myers
Squibb; D3 BIO, INC; F. Hoffmann-La Roche AG; Janssen Pharmaceuticals, Inc.;
Lilly; Merck Sharpe & Dohme; Pfizer; and Takeda Pharmaceutical Company.
Speakers Bureau participant with AstraZeneca; F. Hoffmann-La Roche
AG; and Pfizer.
Co-Chair/Planner
Lori J. Wirth, MD
Associate Professor
Harvard Medical School
Medical Director
Center for Head and Neck Cancers
Massachusetts General Hospital
Boston, Massachusetts
Lori J. Wirth, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie Inc.; Bayer HealthCare
Pharmaceuticals Inc.; Blueprint Medicines Corporation; Coherus BioSciences;
Eisai Co., Ltd.; Ellipses Pharma Ltd; EMD Serono, Inc.; Exelixis, Inc.;
Lilly; Merck & Co., Inc.; and Nested Therapeutics.
Data Safety Monitoring Board for PDS Biotechnology.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
The activity titled “Adapting Our Strategies for Decision-Making in Testing and Treatment of RET-Altered Lung and Thyroid Cancers: A Personalized Learning Journey” has been registered to offer 1.0 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-009-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 1/16/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on January 16, 2025; credit is no longer available.
Adapting Our Strategies for Decision-Making in Testing and Treatment of RET-Altered Lung and Thyroid Cancers: A Personalized Learning Journey
Media: Enduring Material
Activity Release Date: January 17, 2024
Activity Expiration Date: January 16, 2025
Time to Complete Activity: 60 minutes
Activity Description
RET alterations are the primary drivers of tumor growth in a
number of tumor types, with RET fusions relevant in NSCLC, papillary
thyroid cancer, and other solid tumors, and RET point mutations
relevant in sporadic and germline medullary thyroid cancer. Selective RET
inhibitors have become the standard-of-care options and transformed treatment
and subsequent outcomes in RET-altered lung and thyroid cancers.
Thus, upfront detection of RET status is essential in lung and
thyroid cancers to guide treatment decisions, underscoring the importance of
timely, methodologically appropriate, and comprehensive genomic
testing.
This customizable, question-based educational activity provides
evidence-based, expert-guided instruction on biomarker testing strategies,
interpretation of results, and selection of biomarker-driven precision
therapies for patients with advanced/metastatic RET-altered NSCLC
and thyroid cancers.
Target Audience
This activity has been designed to meet the educational needs of oncologists, pathologists, endocrinologists, pulmonologists, advanced practice providers, nurses, pharmacists, and other clinicians involved in the care of patients with lung and thyroid cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Apply best practices and guideline recommendations for biomarker testing for detection of RET alterations in NSCLC and TC
- Examine the evolving evidence supporting the use of RET inhibitors in NSCLC with RET fusions and TC with RET fusions or point mutations
- Integrate evidence-based, biomarker-guided targeted therapy with RET inhibitors into treatment plans for patients with RET-altered NSCLC and TC
- Foster team-based collaboration and shared decision-making to achieve optimal biomarker testing, treatment selection, and outcomes for patients with RET-altered NSCLC and TC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Professor Benjamin Solomon, MBBS, PhD, FRACP, FAHMS
Head Lung Medical Oncology Service
Peter MacCallum Cancer Centre
Melbourne, Australia
Professor Benjamin Solomon, MBBS, PhD, FRACP, FAHMS, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Bristol Myers
Squibb; D3 BIO, INC; F. Hoffmann-La Roche AG; Janssen Pharmaceuticals, Inc.;
Lilly; Merck Sharpe & Dohme; Pfizer; and Takeda Pharmaceutical Company.
Speakers Bureau participant with AstraZeneca; F. Hoffmann-La Roche
AG; and Pfizer.
Co-Chair/Planner
Lori J. Wirth, MD
Associate Professor
Harvard Medical School
Medical Director
Center for Head and Neck Cancers
Massachusetts General Hospital
Boston, Massachusetts
Lori J. Wirth, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie Inc.; Bayer HealthCare
Pharmaceuticals Inc.; Blueprint Medicines Corporation; Coherus BioSciences;
Eisai Co., Ltd.; Ellipses Pharma Ltd; EMD Serono, Inc.; Exelixis, Inc.;
Lilly; Merck & Co., Inc.; and Nested Therapeutics.
Data Safety Monitoring Board for PDS Biotechnology.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
The activity titled “Adapting Our Strategies for Decision-Making in Testing and Treatment of RET-Altered Lung and Thyroid Cancers: A Personalized Learning Journey” has been registered to offer 1.0 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-009-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 1/16/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care
StartThis activity expired on February 16, 2025; credit is no longer available.
From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care
Media: Enduring Material
Activity Release Date: January 17, 2024
Activity Expiration Date: February 16, 2025
Time to Complete Activity: 60 minutes
Activity Description
Can you move from resistance to resilience with BTK inhibitors (BTKi) in relapsed/refractory chronic lymphocytic leukemia (CLL)? Learn how to overcome the well-recognized barriers—including therapeutic intolerance and disease progression—to effective sequential care by joining CLL experts in this case-based educational program. In this activity, developed in collaboration with CLL Society, the experts provide guidance on integrating new sequential BTKi options into everyday clinical practice and share patient scenarios designed to showcase skills that can help overcome medical challenges associated with continuous BTKi therapy over multiple lines of treatment. Don’t miss this opportunity to get back to resilient care with BTKi options in CLL!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, NPs, PAs, nurses, pharmacists, and other care team professionals involved in the management of patients with R/R CLL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance
- Implement best practices for capturing relevant prognostic factors, disease progression, and therapeutic intolerance to guide treatment planning with BTKi in R/R CLL
- Formulate effective sequential treatment plans with BTKi strategies in CLL based on current evidence, prognostic information, and other patient- and disease-specific factors
- Employ team-based approaches to address practical aspects of CLL care when using BTKi, including care coordination, formulary planning, patient education, dosing, and management of treatment-related AEs
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Meghan C. Thompson, MD
Assistant Attending L1, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York
Meghan C. Thompson, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly/Loxo
Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.
Grant/Research Support from AbbVie; AstraZeneca;
BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics.
Research funding goes to Institution.
Co-Chair/Planner
Catherine C. Coombs, MD
Associate Clinical Professor
University of California, Irvine
Orange, California
Catherine C. Coombs, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Allogene
Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen
Pharmaceuticals, Inc.; Lilly; MEI Pharma, Inc.; Mingsight Pharmaceuticals,
Inc.; and Octapharma USA, Inc.
Grant/Research Support from Lilly.
Speaker for AbbVie Inc.; AstraZeneca; BeiGene,
Inc.; and Genentech, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-24-011-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/16/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC
credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For pharmacists, upon receipt of the completed activity
evaluation form, you will receive an email from email@email.peerviewpress.com
within 2 weeks with a link and directions to submit your credit to the NABP
CPE Monitor Service. PVI, PeerView Institute for Medical Education, will
accept your completed evaluation form for up to 30 days and will report your
participation to the NABP only if you provide your NABP e-Profile number and
date of birth. Within 6 weeks, you can view your participation record at the
NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on February 16, 2025; credit is no longer available.
From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care
Media: Enduring Material
Activity Release Date: January 17, 2024
Activity Expiration Date: February 16, 2025
Time to Complete Activity: 60 minutes
Activity Description
Can you move from resistance to resilience with BTK inhibitors (BTKi) in relapsed/refractory chronic lymphocytic leukemia (CLL)? Learn how to overcome the well-recognized barriers—including therapeutic intolerance and disease progression—to effective sequential care by joining CLL experts in this case-based educational program. In this activity, developed in collaboration with CLL Society, the experts provide guidance on integrating new sequential BTKi options into everyday clinical practice and share patient scenarios designed to showcase skills that can help overcome medical challenges associated with continuous BTKi therapy over multiple lines of treatment. Don’t miss this opportunity to get back to resilient care with BTKi options in CLL!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, NPs, PAs, nurses, pharmacists, and other care team professionals involved in the management of patients with R/R CLL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance
- Implement best practices for capturing relevant prognostic factors, disease progression, and therapeutic intolerance to guide treatment planning with BTKi in R/R CLL
- Formulate effective sequential treatment plans with BTKi strategies in CLL based on current evidence, prognostic information, and other patient- and disease-specific factors
- Employ team-based approaches to address practical aspects of CLL care when using BTKi, including care coordination, formulary planning, patient education, dosing, and management of treatment-related AEs
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Meghan C. Thompson, MD
Assistant Attending L1, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York
Meghan C. Thompson, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly/Loxo
Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.
Grant/Research Support from AbbVie; AstraZeneca;
BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics.
Research funding goes to Institution.
Co-Chair/Planner
Catherine C. Coombs, MD
Associate Clinical Professor
University of California, Irvine
Orange, California
Catherine C. Coombs, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Allogene
Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen
Pharmaceuticals, Inc.; Lilly; MEI Pharma, Inc.; Mingsight Pharmaceuticals,
Inc.; and Octapharma USA, Inc.
Grant/Research Support from Lilly.
Speaker for AbbVie Inc.; AstraZeneca; BeiGene,
Inc.; and Genentech, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-24-011-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/16/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC
credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For pharmacists, upon receipt of the completed activity
evaluation form, you will receive an email from email@email.peerviewpress.com
within 2 weeks with a link and directions to submit your credit to the NABP
CPE Monitor Service. PVI, PeerView Institute for Medical Education, will
accept your completed evaluation form for up to 30 days and will report your
participation to the NABP only if you provide your NABP e-Profile number and
date of birth. Within 6 weeks, you can view your participation record at the
NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team
StartThis activity expired on January 11, 2025; credit is no longer available.
Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team
Media: Enduring Material
Activity Release Date: January 12, 2024
Activity Expiration Date: January 11, 2025
Time to Complete Activity: 45 minutes
Activity Description
In this modern era of precision oncology, several therapies targeting pathways that contribute to metastatic colorectal cancer (mCRC) pathogenesis have emerged, including therapies targeting EGFR, VEGF, and the BRAF kinase. Selecting upfront and sequential treatment by considering patient- and tumor-related factors is key to informed shared decision-making and maximizing clinical benefit for patients. This activity features an expert overview of the significance of tumor sidedness in patients with mCRC, how to effectively utilize molecular testing to determine an appropriate course of treatment, and sequencing strategies across the mCRC spectrum.
Target Audience
This activity has been designed to meet the educational needs of oncologists, pathologists, radiologists, oncology nurses, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the care of patients with mCRC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Implement tumor genotyping and evaluation of tumor sidedness at mCRC diagnosis based on current evidence, guideline recommendations, and an understanding of the mechanistic rationale
- Formulate personalized mCRC treatment plans with targeted therapies that are driven by molecular findings and primary tumor localization and supported by the latest evidence and guideline recommendations using a team-based approach
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
John L. Marshall, MD
Director, The Ruesch Center for the Cure of GI Cancers
Frederick P. Smith Endowed Chair
Chief Medical Officer
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center
Washington, District of Columbia
John L. Marshall, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Arcos; AstraZeneca;
Bayer Corporation; Caris Life Sciences; Merck & Co., Inc.; Oradose;
Pfizer; Seagen Inc.; Taiho Oncology, Inc.; Takeda Pharmaceutical
Company Limited; and Zcurex.
Grant/Research Support from Arcos; AstraZeneca; Bayer
Corporation; Caris Life Sciences; Merck & Co., Inc.; Oradose;
Pfizer; Seagen Inc.; Taiho Oncology, Inc.; Takeda Pharmaceutical
Company Limited; and Zcurex.
Other Financial or Material Support Executive role
for Indivumed GmbH.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
The activity titled “Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team” has been registered to offer 0.75 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-066-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 1/11/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of
75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For pharmacists, upon receipt of the completed activity
evaluation form, you will receive an email from email@email.peerviewpress.com
within 2 weeks with a link and directions to submit your credit to the NABP
CPE Monitor Service. PVI, PeerView Institute for Medical Education, will
accept your completed evaluation form for up to 30 days and will report your
participation to the NABP only if you provide your NABP e-Profile number and
date of birth. Within 6 weeks, you can view your participation record at the
NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on January 11, 2025; credit is no longer available.
Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team
Media: Enduring Material
Activity Release Date: January 12, 2024
Activity Expiration Date: January 11, 2025
Time to Complete Activity: 45 minutes
Activity Description
In this modern era of precision oncology, several therapies targeting pathways that contribute to metastatic colorectal cancer (mCRC) pathogenesis have emerged, including therapies targeting EGFR, VEGF, and the BRAF kinase. Selecting upfront and sequential treatment by considering patient- and tumor-related factors is key to informed shared decision-making and maximizing clinical benefit for patients. This activity features an expert overview of the significance of tumor sidedness in patients with mCRC, how to effectively utilize molecular testing to determine an appropriate course of treatment, and sequencing strategies across the mCRC spectrum.
Target Audience
This activity has been designed to meet the educational needs of oncologists, pathologists, radiologists, oncology nurses, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the care of patients with mCRC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Implement tumor genotyping and evaluation of tumor sidedness at mCRC diagnosis based on current evidence, guideline recommendations, and an understanding of the mechanistic rationale
- Formulate personalized mCRC treatment plans with targeted therapies that are driven by molecular findings and primary tumor localization and supported by the latest evidence and guideline recommendations using a team-based approach
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
John L. Marshall, MD
Director, The Ruesch Center for the Cure of GI Cancers
Frederick P. Smith Endowed Chair
Chief Medical Officer
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center
Washington, District of Columbia
John L. Marshall, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Arcos; AstraZeneca;
Bayer Corporation; Caris Life Sciences; Merck & Co., Inc.; Oradose;
Pfizer; Seagen Inc.; Taiho Oncology, Inc.; Takeda Pharmaceutical
Company Limited; and Zcurex.
Grant/Research Support from Arcos; AstraZeneca; Bayer
Corporation; Caris Life Sciences; Merck & Co., Inc.; Oradose;
Pfizer; Seagen Inc.; Taiho Oncology, Inc.; Takeda Pharmaceutical
Company Limited; and Zcurex.
Other Financial or Material Support Executive role
for Indivumed GmbH.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
The activity titled “Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team” has been registered to offer 0.75 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-066-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 1/11/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of
75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For pharmacists, upon receipt of the completed activity
evaluation form, you will receive an email from email@email.peerviewpress.com
within 2 weeks with a link and directions to submit your credit to the NABP
CPE Monitor Service. PVI, PeerView Institute for Medical Education, will
accept your completed evaluation form for up to 30 days and will report your
participation to the NABP only if you provide your NABP e-Profile number and
date of birth. Within 6 weeks, you can view your participation record at the
NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Looking Beyond the Horizon in Gastroesophageal Cancers: Updated Evidence on How Systemic Therapies Are Redefining Care
StartThis activity expired on January 9, 2025; credit is no longer available.
Looking Beyond the Horizon in Gastroesophageal Cancers: Updated Evidence on How Systemic Therapies Are Redefining Care
Media: Enduring Material
Activity Release Date: January 10, 2024
Activity Expiration Date: January 9, 2025
Time to Complete Activity: 60 minutes
Activity Description
With an increasing body of evidence supporting improved approaches for
treating gastroesophageal cancers, oncology professionals can now look beyond
conventional treatment options. Today’s clinicians can integrate personalized
treatment approaches, including immunotherapy and targeted strategies, based
on patient- and disease-specific factors for a superior design of upfront and
sequential therapeutic management.
In this educational activity, experts use illustrative case studies to
provide an overview of the clinical evidence and guideline recommendations
for immunotherapy and targeted agents for gastroesophageal cancers,
strategies for creating personalized treatment plans, and guidance on using a
holistic and team-based approach to address potential challenges associated
with modern therapies.
Target Audience
This activity has been designed to meet the educational needs of oncologists, nurses, nurse practitioners, physician assistants, and other clinicians involved in the care of patients with gastric/GEJ cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Discuss the latest clinical evidence and guideline recommendations supporting the utilization of immunotherapy and targeted agents for patients with gastric/GEJ cancer
- Develop personalized treatment plans for patients with gastric/GEJ cancer based on current clinical evidence, guideline updates, and patient-specific factors
- Integrate a holistic, team-based approach to prevent and address AEs associated with modern systemic therapies for patients with gastric/GEJ cancer to prevent treatment interruptions/disruptions to care
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Jaffer A. Ajani, MD, FASCO
Professor of Medicine, Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Jaffer A. Ajani, MD, FASCO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for American Cancer Society; Amgen Inc.;
Astellas Pharma Inc.; BeiGene, Inc.; Bristol Myers Squibb; Daiichi Sankyo,
Inc.; Eisai Inc.; Gilead Sciences, Inc.; Jazz Pharmaceuticals; Merck & Co.,
Inc.; Novartis Pharmaceuticals Corporation; and Servier.
Grant/Research Support from Amgen Inc.; Astellas Pharma Inc.;
Bristol Myers Squibb; Daiichi Sankyo, Inc., Delta-Fly Pharma, Inc.;
Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Jazz
Pharmaceuticals; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation;
Prolinx, Inc.; Taiho Pharmaceutical Co, Ltd.; Takeda Pharmaceutical Company
Limited; Transcenta; and Zymeworks Inc.
Honoraria from Amgen Inc.; Astellas Pharma Inc.; AstraZeneca;
BeiGene, Inc.; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo,
Inc.; Eisai Inc; Gilead Sciences, Inc.; Jazz Pharmaceuticals; Merck & Co,
Inc.; Novartis Pharmaceuticals Corporation; Servier; and Zymeworks
Inc.
Co-Chair/Planner
Yelena Y. Janjigian*, MD
Professor and Chief of Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
*This activity was developed with Yelena Y. Janjigian, MD, and is not
affiliated in any capacity with Memorial Sloan Kettering Cancer Center.
Yelena Y. Janjigian*, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus
Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea
Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo
Inc.; EMD Serono Inc.; Geneos Therapeutics, Inc.; GlaxoSmithKline; Guardant
Health; Imugene Limited; Inspirna, Inc.; Lilly; Lynx Health; Merck & Co.,
Inc.; Mersana Therapeutics Inc.; Pfizer; Seagen Inc.; Silverback Therapeutics
(ARS Pharmaceuticals) and Zymeworks Inc.
Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer
HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival;
Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.;
Lilly; Merck & Co., Inc.; National Cancer Institute; Transcenta Holding; and
U.S. Department of Defense.
Stock Shareholder in Inspirna, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from Astellas, AstraZeneca, BeiGene, Daiichi Sankyo, Inc., and Merck & Co., Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 1/9/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on January 9, 2025; credit is no longer available.
Looking Beyond the Horizon in Gastroesophageal Cancers: Updated Evidence on How Systemic Therapies Are Redefining Care
Media: Enduring Material
Activity Release Date: January 10, 2024
Activity Expiration Date: January 9, 2025
Time to Complete Activity: 60 minutes
Activity Description
With an increasing body of evidence supporting improved approaches for
treating gastroesophageal cancers, oncology professionals can now look beyond
conventional treatment options. Today’s clinicians can integrate personalized
treatment approaches, including immunotherapy and targeted strategies, based
on patient- and disease-specific factors for a superior design of upfront and
sequential therapeutic management.
In this educational activity, experts use illustrative case studies to
provide an overview of the clinical evidence and guideline recommendations
for immunotherapy and targeted agents for gastroesophageal cancers,
strategies for creating personalized treatment plans, and guidance on using a
holistic and team-based approach to address potential challenges associated
with modern therapies.
Target Audience
This activity has been designed to meet the educational needs of oncologists, nurses, nurse practitioners, physician assistants, and other clinicians involved in the care of patients with gastric/GEJ cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Discuss the latest clinical evidence and guideline recommendations supporting the utilization of immunotherapy and targeted agents for patients with gastric/GEJ cancer
- Develop personalized treatment plans for patients with gastric/GEJ cancer based on current clinical evidence, guideline updates, and patient-specific factors
- Integrate a holistic, team-based approach to prevent and address AEs associated with modern systemic therapies for patients with gastric/GEJ cancer to prevent treatment interruptions/disruptions to care
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Jaffer A. Ajani, MD, FASCO
Professor of Medicine, Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Jaffer A. Ajani, MD, FASCO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for American Cancer Society; Amgen Inc.;
Astellas Pharma Inc.; BeiGene, Inc.; Bristol Myers Squibb; Daiichi Sankyo,
Inc.; Eisai Inc.; Gilead Sciences, Inc.; Jazz Pharmaceuticals; Merck & Co.,
Inc.; Novartis Pharmaceuticals Corporation; and Servier.
Grant/Research Support from Amgen Inc.; Astellas Pharma Inc.;
Bristol Myers Squibb; Daiichi Sankyo, Inc., Delta-Fly Pharma, Inc.;
Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Jazz
Pharmaceuticals; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation;
Prolinx, Inc.; Taiho Pharmaceutical Co, Ltd.; Takeda Pharmaceutical Company
Limited; Transcenta; and Zymeworks Inc.
Honoraria from Amgen Inc.; Astellas Pharma Inc.; AstraZeneca;
BeiGene, Inc.; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo,
Inc.; Eisai Inc; Gilead Sciences, Inc.; Jazz Pharmaceuticals; Merck & Co,
Inc.; Novartis Pharmaceuticals Corporation; Servier; and Zymeworks
Inc.
Co-Chair/Planner
Yelena Y. Janjigian*, MD
Professor and Chief of Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
*This activity was developed with Yelena Y. Janjigian, MD, and is not
affiliated in any capacity with Memorial Sloan Kettering Cancer Center.
Yelena Y. Janjigian*, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus
Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea
Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo
Inc.; EMD Serono Inc.; Geneos Therapeutics, Inc.; GlaxoSmithKline; Guardant
Health; Imugene Limited; Inspirna, Inc.; Lilly; Lynx Health; Merck & Co.,
Inc.; Mersana Therapeutics Inc.; Pfizer; Seagen Inc.; Silverback Therapeutics
(ARS Pharmaceuticals) and Zymeworks Inc.
Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer
HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival;
Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.;
Lilly; Merck & Co., Inc.; National Cancer Institute; Transcenta Holding; and
U.S. Department of Defense.
Stock Shareholder in Inspirna, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from Astellas, AstraZeneca, BeiGene, Daiichi Sankyo, Inc., and Merck & Co., Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 1/9/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC
StartThis activity expired on February 9, 2025; credit is no longer available.
Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC
Media: Enduring Material
Activity Release Date: January 10, 2024
Activity Expiration Date: February 9, 2025
Time to Complete Activity: 60 minutes
Activity Description
The standard of care for patients with HR+, HER2- locally advanced unresectable or metastatic breast cancer (MBC) in the first-line setting involves endocrine therapy in combination with a CDK4/6 inhibitor. However, questions persist regarding the optimal use of each CDK4/6 inhibitor in first- and later-line settings. Ongoing research, fortunately, is providing new insights into the use of CDK4/6 inhibitors. Additionally, a number of investigational therapies with the potential to change clinical practice are showing great promise, with some recently approved in the metastatic setting. These investigational therapies include novel oral SERDs, ATK inhibition, and antibody–drug conjugates, such as those targeting HER2 and TROP2. With these therapies proving their clinical potential, it is essential to learn how to best integrate them into the current treatment arsenal. Furthermore, various patient- and disease-related factors such as age, HR status, metastatic sites, visceral involvement, endocrine resistance, tumor grade, disease-free interval, and molecular profile must be considered for optimal individualized therapy as well. In this PeerView Live virtual workshop, presented through a case-based framework, leading experts review the latest clinical evidence and provide practical strategies on navigating the complexities of clinical decision-making and selection and sequencing of therapies. The panel also addresses the nuances of treatment delivery and best practices for mitigating and managing adverse events associated with CDK4/6 inhibitors to help patients with HR+, HER2- MBC achieve the best possible outcomes.
Target Audience
This activity has been designed to meet the educational needs of oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with HR+, HER2- MBC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Evaluate the latest efficacy and safety data supporting the use of CDK4/6 inhibitors, as well as new and emerging treatment options for patients with HR+, HER2- MBC, considering their evolving roles in clinical practice
- Develop individualized treatment plans that integrate CDK4/6 inhibitor therapy for patients with HR+, HER2- MBC, based on the latest evidence, guidelines, and assessment of drug-, tumor/disease-, and patient-related factors
- Implement team-based strategies to achieve optimal treatment adherence and persistence, as well as prevent and mitigate adverse events associated with different CDK4/6 inhibitors in the management of HR+, HER2- MBC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, Texas
Joyce O’Shaughnessy, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Agendia;
Amgen Inc.; Aptitude Health; AstraZeneca; Bayer HealthCare Pharmaceuticals,
Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.;
Duality Biologics; Eisai Inc.; F. Hoffmann-La Roche Ltd.; G1 Therapeutics,
Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GRAIL, Inc.; Halozyme, Inc.;
Heron Therapeutics, Inc.; Immunomedics, Inc.; Ipsen Biopharmaceuticals, Inc.;
Lilly; Merck & Co., Inc.; Myriad Genetics, Inc.; Nektar; Novartis
Pharmaceuticals Corporation; Ontada LLC; Pfizer; Pharmacyclics LLC; Pierre
Fabre group; prIME Oncology; Puma Biotechnology, Inc.; Samsung Bioepis;
Sanofi; Scorpion Therapeutics, Inc.; Seagen Inc.; Stemline Therapeutics,
Inc./The Menarini Group; Syndax Pharmaceuticals Inc.; Synthon; Taiho
Oncology, Inc.; and Takeda Pharmaceutical Company Limited.
Faculty/Planner
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Associate Director
Susan F. Smith Center for Women’s Cancers
Senior Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Sara M. Tolaney, MD, MPH, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for 4D pharma plc; Aadi
Bioscience, Inc.; ARC Therapeutics; Artios Pharma; AstraZeneca; Bayer
HealthCare Pharmaceuticals, Inc.; BeyondSpring Pharmaceuticals Inc.;
Blueprint Medicines; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi
Sankyo Inc.; eFFECTOR Therapeutics; Eisai Inc.; Exelixis, Inc.; Genentech,
Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Incyte; Jazz
Pharmaceuticals; Lilly; Merck & Co., Inc.; Myovant Sciences Ltd.; Natera;
Novartis Pharmaceuticals Corporation; Pfizer; Reveal Genomics; Sanofi;
Seattle Genetics, Inc.; Stemline Therapeutics, Inc./The Menarini
Group; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis;
Zetagen; and Zymeworks Inc.
Grant/Research Support from AstraZeneca; Bristol Myers
Squibb; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.;
Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly;
Merck & Co., Inc.; NanoString Technologies Inc.; Nektar; Novartis
Pharmaceuticals Corporation; Pfizer; Sanofi; and Seattle Genetics, Inc.
Other Financial or Material Support from Steering
committee for CytomX Therapeutics, Inc. and OncXerna Therapeutics, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-004-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/9/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC
credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For pharmacists, upon receipt of the completed activity
evaluation form, you will receive an email from email@email.peerviewpress.com
within 2 weeks with a link and directions to submit your credit to the NABP
CPE Monitor Service. PVI, PeerView Institute for Medical Education, will
accept your completed evaluation form for up to 30 days and will report your
participation to the NABP only if you provide your NABP e-Profile number and
date of birth. Within 6 weeks, you can view your participation record at the
NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on February 9, 2025; credit is no longer available.
Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC
Media: Enduring Material
Activity Release Date: January 10, 2024
Activity Expiration Date: February 9, 2025
Time to Complete Activity: 60 minutes
Activity Description
The standard of care for patients with HR+, HER2- locally advanced unresectable or metastatic breast cancer (MBC) in the first-line setting involves endocrine therapy in combination with a CDK4/6 inhibitor. However, questions persist regarding the optimal use of each CDK4/6 inhibitor in first- and later-line settings. Ongoing research, fortunately, is providing new insights into the use of CDK4/6 inhibitors. Additionally, a number of investigational therapies with the potential to change clinical practice are showing great promise, with some recently approved in the metastatic setting. These investigational therapies include novel oral SERDs, ATK inhibition, and antibody–drug conjugates, such as those targeting HER2 and TROP2. With these therapies proving their clinical potential, it is essential to learn how to best integrate them into the current treatment arsenal. Furthermore, various patient- and disease-related factors such as age, HR status, metastatic sites, visceral involvement, endocrine resistance, tumor grade, disease-free interval, and molecular profile must be considered for optimal individualized therapy as well. In this PeerView Live virtual workshop, presented through a case-based framework, leading experts review the latest clinical evidence and provide practical strategies on navigating the complexities of clinical decision-making and selection and sequencing of therapies. The panel also addresses the nuances of treatment delivery and best practices for mitigating and managing adverse events associated with CDK4/6 inhibitors to help patients with HR+, HER2- MBC achieve the best possible outcomes.
Target Audience
This activity has been designed to meet the educational needs of oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with HR+, HER2- MBC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Evaluate the latest efficacy and safety data supporting the use of CDK4/6 inhibitors, as well as new and emerging treatment options for patients with HR+, HER2- MBC, considering their evolving roles in clinical practice
- Develop individualized treatment plans that integrate CDK4/6 inhibitor therapy for patients with HR+, HER2- MBC, based on the latest evidence, guidelines, and assessment of drug-, tumor/disease-, and patient-related factors
- Implement team-based strategies to achieve optimal treatment adherence and persistence, as well as prevent and mitigate adverse events associated with different CDK4/6 inhibitors in the management of HR+, HER2- MBC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, Texas
Joyce O’Shaughnessy, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Agendia;
Amgen Inc.; Aptitude Health; AstraZeneca; Bayer HealthCare Pharmaceuticals,
Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.;
Duality Biologics; Eisai Inc.; F. Hoffmann-La Roche Ltd.; G1 Therapeutics,
Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GRAIL, Inc.; Halozyme, Inc.;
Heron Therapeutics, Inc.; Immunomedics, Inc.; Ipsen Biopharmaceuticals, Inc.;
Lilly; Merck & Co., Inc.; Myriad Genetics, Inc.; Nektar; Novartis
Pharmaceuticals Corporation; Ontada LLC; Pfizer; Pharmacyclics LLC; Pierre
Fabre group; prIME Oncology; Puma Biotechnology, Inc.; Samsung Bioepis;
Sanofi; Scorpion Therapeutics, Inc.; Seagen Inc.; Stemline Therapeutics,
Inc./The Menarini Group; Syndax Pharmaceuticals Inc.; Synthon; Taiho
Oncology, Inc.; and Takeda Pharmaceutical Company Limited.
Faculty/Planner
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Associate Director
Susan F. Smith Center for Women’s Cancers
Senior Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Sara M. Tolaney, MD, MPH, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for 4D pharma plc; Aadi
Bioscience, Inc.; ARC Therapeutics; Artios Pharma; AstraZeneca; Bayer
HealthCare Pharmaceuticals, Inc.; BeyondSpring Pharmaceuticals Inc.;
Blueprint Medicines; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi
Sankyo Inc.; eFFECTOR Therapeutics; Eisai Inc.; Exelixis, Inc.; Genentech,
Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Incyte; Jazz
Pharmaceuticals; Lilly; Merck & Co., Inc.; Myovant Sciences Ltd.; Natera;
Novartis Pharmaceuticals Corporation; Pfizer; Reveal Genomics; Sanofi;
Seattle Genetics, Inc.; Stemline Therapeutics, Inc./The Menarini
Group; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis;
Zetagen; and Zymeworks Inc.
Grant/Research Support from AstraZeneca; Bristol Myers
Squibb; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.;
Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly;
Merck & Co., Inc.; NanoString Technologies Inc.; Nektar; Novartis
Pharmaceuticals Corporation; Pfizer; Sanofi; and Seattle Genetics, Inc.
Other Financial or Material Support from Steering
committee for CytomX Therapeutics, Inc. and OncXerna Therapeutics, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-004-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/9/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC
credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For pharmacists, upon receipt of the completed activity
evaluation form, you will receive an email from email@email.peerviewpress.com
within 2 weeks with a link and directions to submit your credit to the NABP
CPE Monitor Service. PVI, PeerView Institute for Medical Education, will
accept your completed evaluation form for up to 30 days and will report your
participation to the NABP only if you provide your NABP e-Profile number and
date of birth. Within 6 weeks, you can view your participation record at the
NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Getting Personal: Reassessing HIV Management to Better Individualize Treatment Across the Ages
StartThis activity expired on December 12, 2024; credit is no longer available.
Getting Personal: Reassessing HIV Management to Better Individualize Treatment Across the Ages
Media: Enduring Material
Activity Release Date: December 13, 2023
Activity Expiration Date: December 12, 2024
Time to Complete Activity: 60 minutes
Activity Description
In this activity, an expert discusses identifying barriers that threaten ending the HIV epidemic, current and emerging treatment options in HIV management, and ways to personalize treatment for patients living with HIV to improve outcomes and adherence.
Target Audience
This activity has been designed to meet the educational needs of HIV care providers, primary care providers and general practitioners, advanced practice providers, nurses, pharmacists, and other professionals involved in the care of patients living with HIV.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify patient barriers that may contribute to poor persistence with HIV treatment
- Counsel patients living with HIV about the benefits and flexibility of current and emerging options in treatment and the importance of remaining adherent to therapy
- Personalize treatment for patients living with HIV based on therapeutic mechanism of action, route of administration, efficacy, safety, and resistance profiles, considering each patient’s individual needs across the age span (adolescence, child-bearing years, aged >65 years)
- Implement team-based HIV management strategies that ensure health equity, access and adherence to treatment, and ongoing monitoring for resistance
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Professor Chloe Orkin
Professor of Infection and Inequities
Queen Mary University of London
Barts Health NHS Trust
London, England, United Kingdom
Professor Chloe Orkin has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; GSK; Merck
Sharp & Dohme; and ViiV Healthcare group of companies.
Grant/Research Support from Gilead Sciences, Inc. and ViiV
Healthcare group of companies.
Speaker for Gilead Sciences, Inc.; GSK; Merck Sharp & Dohme;
and ViiV Healthcare group of companies.
Patient Advocate/Planner
Shawnte' Spriggs
Shawnte' Spriggs has no financial interests/relationships or affiliations in relation to this activity.
Patient Advocate/Planner
Donald Young
Donald Young has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program has been supported by an independent educational grant from Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-069-H02-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 12/12/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on December 12, 2024; credit is no longer available.
Getting Personal: Reassessing HIV Management to Better Individualize Treatment Across the Ages
Media: Enduring Material
Activity Release Date: December 13, 2023
Activity Expiration Date: December 12, 2024
Time to Complete Activity: 60 minutes
Activity Description
In this activity, an expert discusses identifying barriers that threaten ending the HIV epidemic, current and emerging treatment options in HIV management, and ways to personalize treatment for patients living with HIV to improve outcomes and adherence.
Target Audience
This activity has been designed to meet the educational needs of HIV care providers, primary care providers and general practitioners, advanced practice providers, nurses, pharmacists, and other professionals involved in the care of patients living with HIV.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify patient barriers that may contribute to poor persistence with HIV treatment
- Counsel patients living with HIV about the benefits and flexibility of current and emerging options in treatment and the importance of remaining adherent to therapy
- Personalize treatment for patients living with HIV based on therapeutic mechanism of action, route of administration, efficacy, safety, and resistance profiles, considering each patient’s individual needs across the age span (adolescence, child-bearing years, aged >65 years)
- Implement team-based HIV management strategies that ensure health equity, access and adherence to treatment, and ongoing monitoring for resistance
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Professor Chloe Orkin
Professor of Infection and Inequities
Queen Mary University of London
Barts Health NHS Trust
London, England, United Kingdom
Professor Chloe Orkin has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; GSK; Merck
Sharp & Dohme; and ViiV Healthcare group of companies.
Grant/Research Support from Gilead Sciences, Inc. and ViiV
Healthcare group of companies.
Speaker for Gilead Sciences, Inc.; GSK; Merck Sharp & Dohme;
and ViiV Healthcare group of companies.
Patient Advocate/Planner
Shawnte' Spriggs
Shawnte' Spriggs has no financial interests/relationships or affiliations in relation to this activity.
Patient Advocate/Planner
Donald Young
Donald Young has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program has been supported by an independent educational grant from Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-069-H02-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 12/12/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making
StartThis activity expired on December 12, 2024; credit is no longer available.
Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making
Media: Enduring Material
Activity Release Date: December 13, 2023
Activity Expiration Date: December 12, 2024
Time to Complete Activity: 30 minutes
Activity Description
The establishment of immunotherapy-based regimens in the modern treatment
paradigm for upper GI Cancers, including gastric and gastroesophageal
junction (GEJ) cancers, is placing increased importance on close
collaboration between the clinical care team and patients and caregivers, to
promote engagement in a process of informed shared decision-making (SDM) when
selecting treatment plans that are tailored to patient-specific needs,
values, and preferences.
In this PeerView activity, an oncologist, who is an expert in GI cancers,
will present practice-changing evidence for integrating immunotherapy
approaches into treatment plans; give insights on the rationale and benefits
of engaging patients in informed shared decision-making when choosing
treatment options; and explore the available tools when making informed
shared decisions about immuno-oncology strategies as part of a team-based,
equitable management approach, using the CheckMate -649 plain language
summary as an example that can be downloaded for your use. Don’t miss this
unique opportunity to enhance your skills in patient engagement to promote
SDM in your practice!
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and other care team professionals involved in the treatment of patients with upper GI cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe current evidence-based, guideline-recommended protocols for integrating immuno-oncology approaches into treatment plans for patients with upper GI cancers across disease settings
- Explain the benefits of engaging patients with upper GI cancers in informed shared decision-making by the healthcare team when choosing a treatment option including the effects on patient engagement in the selected treatment plan
- Utilize available tools including plain language summaries when making informed shared decisions about including immuno-oncology strategies as part of a team-based, equitable management approach to upper GI malignancies
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Yelena Y. Janjigian*, MD
Professor and Chief of Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
*This activity was developed with Yelena Y. Janjigian, MD, and is not
affiliated in any capacity with Memorial Sloan Kettering Cancer Center.
Yelena Y. Janjigian*, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus
Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea
Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo
Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.;
Lilly; Merck & Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer;
Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and
Zymeworks Inc.
Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer
HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival;
Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.;
Lilly; Merck & Co., Inc.; National Cancer Institute; Transcenta Holding; and
U.S. Department of Defense.
Stock Shareholder in Inspirna, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and no contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-073-H01-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 12/12/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on December 12, 2024; credit is no longer available.
Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making
Media: Enduring Material
Activity Release Date: December 13, 2023
Activity Expiration Date: December 12, 2024
Time to Complete Activity: 30 minutes
Activity Description
The establishment of immunotherapy-based regimens in the modern treatment
paradigm for upper GI Cancers, including gastric and gastroesophageal
junction (GEJ) cancers, is placing increased importance on close
collaboration between the clinical care team and patients and caregivers, to
promote engagement in a process of informed shared decision-making (SDM) when
selecting treatment plans that are tailored to patient-specific needs,
values, and preferences.
In this PeerView activity, an oncologist, who is an expert in GI cancers,
will present practice-changing evidence for integrating immunotherapy
approaches into treatment plans; give insights on the rationale and benefits
of engaging patients in informed shared decision-making when choosing
treatment options; and explore the available tools when making informed
shared decisions about immuno-oncology strategies as part of a team-based,
equitable management approach, using the CheckMate -649 plain language
summary as an example that can be downloaded for your use. Don’t miss this
unique opportunity to enhance your skills in patient engagement to promote
SDM in your practice!
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and other care team professionals involved in the treatment of patients with upper GI cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe current evidence-based, guideline-recommended protocols for integrating immuno-oncology approaches into treatment plans for patients with upper GI cancers across disease settings
- Explain the benefits of engaging patients with upper GI cancers in informed shared decision-making by the healthcare team when choosing a treatment option including the effects on patient engagement in the selected treatment plan
- Utilize available tools including plain language summaries when making informed shared decisions about including immuno-oncology strategies as part of a team-based, equitable management approach to upper GI malignancies
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Yelena Y. Janjigian*, MD
Professor and Chief of Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
*This activity was developed with Yelena Y. Janjigian, MD, and is not
affiliated in any capacity with Memorial Sloan Kettering Cancer Center.
Yelena Y. Janjigian*, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus
Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea
Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo
Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.;
Lilly; Merck & Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer;
Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and
Zymeworks Inc.
Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer
HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival;
Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.;
Lilly; Merck & Co., Inc.; National Cancer Institute; Transcenta Holding; and
U.S. Department of Defense.
Stock Shareholder in Inspirna, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and no contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-073-H01-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 12/12/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
The ABCs of ADCs for Gynecologic Cancer: Expert Insights on Effective Implementation and Practical Tips for Use in Patients With Cervical, Ovarian, or Endometrial Cancer
StartThis activity expired on December 10, 2024; credit is no longer available.
The ABCs of ADCs for Gynecologic Cancer: Expert Insights on Effective Implementation and Practical Tips for Use in Patients With Cervical, Ovarian, or Endometrial Cancer
Media: Enduring Material
Activity Release Date: December 11, 2023
Activity Expiration Date: December 10, 2024
Time to Complete Activity: 30 minutes
Activity Description
Antibody–drug conjugates (ADCs) are associated with positive clinical trial outcomes and regulatory approvals in the treatment of patients with gynecologic malignancies such as cervical, ovarian, and endometrial cancers. As patient care shifts from largely chemotherapy-focused approaches to modern therapeutics, professionals must stay informed on the latest data supporting ADCs and best practices for using ADC-based regimens in the clinic. In this video-based activity, expert faculty review evidence on the use of ADCs in gynecologic cancers, provide strategies for developing individualized treatment plans that incorporate ADC-based regimens (including via clinical trial enrollment), and offer guidance on team-based approaches to managing AEs in patients with gynecologic cancers undergoing treatment with ADCs.
Target Audience
This activity has been designed to meet the educational needs of gynecologic oncologists, medical oncologists, and other healthcare professionals involved in the care of patients with gynecologic cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the properties, mechanisms of action, and latest clinical evidence of validated and emerging antibody–drug conjugates (ADCs) in gynecologic cancers
- Select approved and emerging ADCs for the treatment of patients with gynecologic cancer within the context of clinical practice or through clinical trial participation
- Employ evidence-based and team-based strategies to mitigate and manage treatment-related adverse events in patients with gynecologic cancer receiving ADC therapy and provide education, guidance, and counseling for optimal use
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Bradley J. Monk, MD, FACS, FACOG
Professor
Division of Gynecologic Oncology
University of Arizona College of Medicine
Creighton University School of Medicine
Phoenix, Arizona
Bradley J. Monk, MD, FACS, FACOG, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Acrivon Therapeutics; Adaptimmune
Therapeutics plc.; Agenus Inc.; Akeso Biopharma Co., Ltd.; Amgen Inc.;
Aravive; AstraZeneca; Bayer Corporation; Clovis Oncology; Eisai Inc.; Elevar,
LLC; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Genmab
A/S/Seagen Inc.; The GOG Foundation Inc; Gradalis, Inc.; ImmunoGen, Inc.;
Iovance Biotherapeutics, Inc.; Jiangsu Hengrui Pharmaceuticals Co., Ltd.;
Karyopharm; Laekna Therapeutics; Merck & Co., Inc.; Mersana Therapeutics;
Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Novocure GmbH;
OncoC4, Inc.; Panavance Therapeutics Inc.; Pfizer; Pieris Pharmaceuticals,
Inc.; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; Sorrento
Therapeutics, Inc.; TESARO, Inc./GlaxoSmithKline; US Oncology Research, LLC;
VBL Therapeutics; Verastem, Inc.; and Zentalis Pharmaceuticals.
Grant/Research Support from US Oncology Research, LLC.
Speaker for AstraZeneca; Clovis Oncology; Eisai Inc.; F.
Hoffmann-La Roche Ltd./Genentech, Inc.; Merck & Co., Inc.;
and TESARO, Inc./GlaxoSmithKline.
Faculty/Planner
Ana Oaknin, MD, PhD
Head of Gynaecological Cancer Program
Medical Oncology Department
Vall d'Hebron University Hospital
Vall d'Hebron Institute of Oncology (VHIO)
Barcelona, Spain
Ana Oaknin, MD, PhD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Agenus Inc.; AstraZeneca; Clovis
Oncology; Corcept Therapeutics; Deciphera Pharmaceuticals; Eisai Co., Ltd.;
EMD Serono; Exelisis, Inc.; F. Hoffmann-La Roche; Genmab A/S;
GlaxoSmithKline; ImmunoGen, Inc.; iTeos Therapeutics; Merck Sharp & Dohme de
Espana SA; Mersana Therapeutics; Novocure GmbH; OncXerna Therapeutics, Inc.;
Pharma Mar SA; Regeneron Pharmaceuticals Inc.; Seagen, Inc.; Shattuck Labs,
Inc.; and Sutro Biopharma, Inc.
Grant/Research Support from AbbVie Deutschland; Advaxis Inc.;
Aeterna Zentaris; Amgen Inc.; Aprea Therapeutics AB; Bristol Myers Squibb;
Clovis Oncology; Eisai Co., Ltd.; F. Hoffmann-La Roche; ImmunoGen, Inc.;
Merck Sharp & Dohme de Espana SA; Millennium Pharmaceuticals Inc.; Pharma Mar
SA; Regeneron Pharmaceuticals Inc; and Tesaro.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., Eisai Inc., and Seagen and Genmab.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 12/10/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on December 10, 2024; credit is no longer available.
The ABCs of ADCs for Gynecologic Cancer: Expert Insights on Effective Implementation and Practical Tips for Use in Patients With Cervical, Ovarian, or Endometrial Cancer
Media: Enduring Material
Activity Release Date: December 11, 2023
Activity Expiration Date: December 10, 2024
Time to Complete Activity: 30 minutes
Activity Description
Antibody–drug conjugates (ADCs) are associated with positive clinical trial outcomes and regulatory approvals in the treatment of patients with gynecologic malignancies such as cervical, ovarian, and endometrial cancers. As patient care shifts from largely chemotherapy-focused approaches to modern therapeutics, professionals must stay informed on the latest data supporting ADCs and best practices for using ADC-based regimens in the clinic. In this video-based activity, expert faculty review evidence on the use of ADCs in gynecologic cancers, provide strategies for developing individualized treatment plans that incorporate ADC-based regimens (including via clinical trial enrollment), and offer guidance on team-based approaches to managing AEs in patients with gynecologic cancers undergoing treatment with ADCs.
Target Audience
This activity has been designed to meet the educational needs of gynecologic oncologists, medical oncologists, and other healthcare professionals involved in the care of patients with gynecologic cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the properties, mechanisms of action, and latest clinical evidence of validated and emerging antibody–drug conjugates (ADCs) in gynecologic cancers
- Select approved and emerging ADCs for the treatment of patients with gynecologic cancer within the context of clinical practice or through clinical trial participation
- Employ evidence-based and team-based strategies to mitigate and manage treatment-related adverse events in patients with gynecologic cancer receiving ADC therapy and provide education, guidance, and counseling for optimal use
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Bradley J. Monk, MD, FACS, FACOG
Professor
Division of Gynecologic Oncology
University of Arizona College of Medicine
Creighton University School of Medicine
Phoenix, Arizona
Bradley J. Monk, MD, FACS, FACOG, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Acrivon Therapeutics; Adaptimmune
Therapeutics plc.; Agenus Inc.; Akeso Biopharma Co., Ltd.; Amgen Inc.;
Aravive; AstraZeneca; Bayer Corporation; Clovis Oncology; Eisai Inc.; Elevar,
LLC; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Genmab
A/S/Seagen Inc.; The GOG Foundation Inc; Gradalis, Inc.; ImmunoGen, Inc.;
Iovance Biotherapeutics, Inc.; Jiangsu Hengrui Pharmaceuticals Co., Ltd.;
Karyopharm; Laekna Therapeutics; Merck & Co., Inc.; Mersana Therapeutics;
Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Novocure GmbH;
OncoC4, Inc.; Panavance Therapeutics Inc.; Pfizer; Pieris Pharmaceuticals,
Inc.; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; Sorrento
Therapeutics, Inc.; TESARO, Inc./GlaxoSmithKline; US Oncology Research, LLC;
VBL Therapeutics; Verastem, Inc.; and Zentalis Pharmaceuticals.
Grant/Research Support from US Oncology Research, LLC.
Speaker for AstraZeneca; Clovis Oncology; Eisai Inc.; F.
Hoffmann-La Roche Ltd./Genentech, Inc.; Merck & Co., Inc.;
and TESARO, Inc./GlaxoSmithKline.
Faculty/Planner
Ana Oaknin, MD, PhD
Head of Gynaecological Cancer Program
Medical Oncology Department
Vall d'Hebron University Hospital
Vall d'Hebron Institute of Oncology (VHIO)
Barcelona, Spain
Ana Oaknin, MD, PhD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Agenus Inc.; AstraZeneca; Clovis
Oncology; Corcept Therapeutics; Deciphera Pharmaceuticals; Eisai Co., Ltd.;
EMD Serono; Exelisis, Inc.; F. Hoffmann-La Roche; Genmab A/S;
GlaxoSmithKline; ImmunoGen, Inc.; iTeos Therapeutics; Merck Sharp & Dohme de
Espana SA; Mersana Therapeutics; Novocure GmbH; OncXerna Therapeutics, Inc.;
Pharma Mar SA; Regeneron Pharmaceuticals Inc.; Seagen, Inc.; Shattuck Labs,
Inc.; and Sutro Biopharma, Inc.
Grant/Research Support from AbbVie Deutschland; Advaxis Inc.;
Aeterna Zentaris; Amgen Inc.; Aprea Therapeutics AB; Bristol Myers Squibb;
Clovis Oncology; Eisai Co., Ltd.; F. Hoffmann-La Roche; ImmunoGen, Inc.;
Merck Sharp & Dohme de Espana SA; Millennium Pharmaceuticals Inc.; Pharma Mar
SA; Regeneron Pharmaceuticals Inc; and Tesaro.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., Eisai Inc., and Seagen and Genmab.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 12/10/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Roadmap to Success With Immunotherapy's Dynamic Evolution in Metastatic, Locally Advanced, and Early-Stage NSCLC: Multidisciplinary Best Practices for Exemplary Care
StartThis activity expired on December 29, 2024; credit is no longer available.
Roadmap to Success With Immunotherapy's Dynamic Evolution in Metastatic, Locally Advanced, and Early-Stage NSCLC: Multidisciplinary Best Practices for Exemplary Care
Media: Enduring Material
Activity Release Date: November 30, 2023
Activity Expiration Date: December 29, 2024
Time to Complete Activity: 90 minutes
Activity Description
Since the first approval of an immune checkpoint inhibitor (ICI) in 2015,
the evolution of immunotherapy has drastically changed the lung cancer
treatment landscape. There are now many monotherapy and combinatorial options
available for patients with metastatic NSCLC, allowing individualized therapy
according to various factors. In locally advanced unresectable stage III
NSCLC, consolidation immunotherapy following chemoradiation is routinely
used, and other ICI-based multimodal approaches are being investigated in
clinical trials. Expanding to earlier stages, ICIs have received regulatory
approvals in adjuvant, neoadjuvant, and perioperative (both adjuvant and
neoadjuvant) settings, changing the standards of care for resectable stage
I-III NSCLC. Ongoing studies are expected to further broaden the impact and
refine the use of immunotherapy in lung cancer in the near future.
This PeerView educational activity, based on a recent live symposium,
provides comprehensive guidance on the evidence-based integration and
practical use of current and emerging immunotherapy options as well as
leveraging multidisciplinary and interprofessional collaboration in the
context of new requirements and changing best practices to improve patient
outcomes throughout the NSCLC disease continuum. Experts present illustrative
case scenarios to frame in-depth reviews and interpretations of evidence
supporting the use of immunotherapies in NSCLC to equip participants with the
tools and strategies needed to improve patient outcomes.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, pathologists, advanced practice clinicians, and other healthcare professionals involved in the care of patients with NSCLC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Evaluate the latest evidence supporting the use of current and emerging ICIs and combinations in metastatic, stage III unresectable, and stage I-III resectable NSCLC
- Determine the most appropriate ICI-based treatment approaches for eligible patients with metastatic, stage III unresectable, and stage I-III resectable NSCLC
- Implement best practices for multidisciplinary and interprofessional collaboration and patient-centered care to optimally integrate immunotherapies throughout the NSCLC disease continuum, maximize their benefits, and minimize their risks during treatment and survivorship
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Matthew A. Gubens, MD, MS, FASCO
Professor of Medicine
Medical Director, Thoracic Medical Oncology
Division of Hematology/Oncology
Department of Medicine
University of California San Francisco
San Francisco, California
Matthew A. Gubens, MD, MS, FASCO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AnHeart Therapeutics; AstraZeneca;
Atreca, Inc.; Bristol Myers Squibb; Cardinal Health, Inc.; Genentech, Inc./F.
Hoffmann-La Roche AG; Genzyme; Gilead Sciences, Inc.; Guardant Health;
Invitae Corporation; iTeos Therapeutics; Merus; Sanofi; Summit; and
Surface.
Grant/Research Support from Amgen; Celgene Corporation; Johnson &
Johnson; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OncoMed
Pharmaceuticals, Inc.; and Trizell. Research funding to
institution.
Faculty/Planner
Jessica Donington, MD
Professor of Surgery
Chief, Section of Thoracic Surgery
The University of Chicago Medicine
Chicago, Illinois
Jessica Donington, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers
Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co.,
Inc.
Grant/Research Support from AstraZeneca; Bristol Myers Squibb;
Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.
Faculty/Planner
Elaine Shum, MD
Assistant Professor, Department of Medicine
NYU Grossman School of Medicine
Thoracic Medical Oncologist
NYU Perlmutter Cancer Center
New York, New York
Elaine Shum, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AstraZeneca; Blueprint Medicines
Corporation; Boehringer Ingelheim International GmbH; Genentech, Inc.; Gilead
Sciences, Inc.; and Regeneron Pharmaceuticals Inc.
Grant/Research Support from DELFI Diagnostics.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an independent educational grant from AstraZeneca.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 12/29/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on December 29, 2024; credit is no longer available.
Roadmap to Success With Immunotherapy's Dynamic Evolution in Metastatic, Locally Advanced, and Early-Stage NSCLC: Multidisciplinary Best Practices for Exemplary Care
Media: Enduring Material
Activity Release Date: November 30, 2023
Activity Expiration Date: December 29, 2024
Time to Complete Activity: 90 minutes
Activity Description
Since the first approval of an immune checkpoint inhibitor (ICI) in 2015,
the evolution of immunotherapy has drastically changed the lung cancer
treatment landscape. There are now many monotherapy and combinatorial options
available for patients with metastatic NSCLC, allowing individualized therapy
according to various factors. In locally advanced unresectable stage III
NSCLC, consolidation immunotherapy following chemoradiation is routinely
used, and other ICI-based multimodal approaches are being investigated in
clinical trials. Expanding to earlier stages, ICIs have received regulatory
approvals in adjuvant, neoadjuvant, and perioperative (both adjuvant and
neoadjuvant) settings, changing the standards of care for resectable stage
I-III NSCLC. Ongoing studies are expected to further broaden the impact and
refine the use of immunotherapy in lung cancer in the near future.
This PeerView educational activity, based on a recent live symposium,
provides comprehensive guidance on the evidence-based integration and
practical use of current and emerging immunotherapy options as well as
leveraging multidisciplinary and interprofessional collaboration in the
context of new requirements and changing best practices to improve patient
outcomes throughout the NSCLC disease continuum. Experts present illustrative
case scenarios to frame in-depth reviews and interpretations of evidence
supporting the use of immunotherapies in NSCLC to equip participants with the
tools and strategies needed to improve patient outcomes.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, pathologists, advanced practice clinicians, and other healthcare professionals involved in the care of patients with NSCLC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Evaluate the latest evidence supporting the use of current and emerging ICIs and combinations in metastatic, stage III unresectable, and stage I-III resectable NSCLC
- Determine the most appropriate ICI-based treatment approaches for eligible patients with metastatic, stage III unresectable, and stage I-III resectable NSCLC
- Implement best practices for multidisciplinary and interprofessional collaboration and patient-centered care to optimally integrate immunotherapies throughout the NSCLC disease continuum, maximize their benefits, and minimize their risks during treatment and survivorship
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Matthew A. Gubens, MD, MS, FASCO
Professor of Medicine
Medical Director, Thoracic Medical Oncology
Division of Hematology/Oncology
Department of Medicine
University of California San Francisco
San Francisco, California
Matthew A. Gubens, MD, MS, FASCO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AnHeart Therapeutics; AstraZeneca;
Atreca, Inc.; Bristol Myers Squibb; Cardinal Health, Inc.; Genentech, Inc./F.
Hoffmann-La Roche AG; Genzyme; Gilead Sciences, Inc.; Guardant Health;
Invitae Corporation; iTeos Therapeutics; Merus; Sanofi; Summit; and
Surface.
Grant/Research Support from Amgen; Celgene Corporation; Johnson &
Johnson; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OncoMed
Pharmaceuticals, Inc.; and Trizell. Research funding to
institution.
Faculty/Planner
Jessica Donington, MD
Professor of Surgery
Chief, Section of Thoracic Surgery
The University of Chicago Medicine
Chicago, Illinois
Jessica Donington, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers
Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co.,
Inc.
Grant/Research Support from AstraZeneca; Bristol Myers Squibb;
Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.
Faculty/Planner
Elaine Shum, MD
Assistant Professor, Department of Medicine
NYU Grossman School of Medicine
Thoracic Medical Oncologist
NYU Perlmutter Cancer Center
New York, New York
Elaine Shum, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AstraZeneca; Blueprint Medicines
Corporation; Boehringer Ingelheim International GmbH; Genentech, Inc.; Gilead
Sciences, Inc.; and Regeneron Pharmaceuticals Inc.
Grant/Research Support from DELFI Diagnostics.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an independent educational grant from AstraZeneca.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 12/29/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enhancing Outcomes With Potent CD38 Antibody Platforms
StartThis activity expired on November 29, 2024; credit is no longer available.
The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enhancing Outcomes With Potent CD38 Antibody Platforms
Media: Enduring Material
Activity Release Date: November 30, 2023
Activity Expiration Date: November 29, 2024
Time to Complete Activity: 60 minutes
Activity Description
Although innovative therapeutics have led to better overall outcomes, multiple myeloma (MM) remains an incurable disease that presents a range of challenges, particularly in relapsed/refractory (RR) settings. In this educational activity, PeerView partners with the HealthTree Foundation for Multiple Myeloma to address these challenges by bringing together MM experts to demonstrate how the healthcare team can enhance care through the judicious selection and sequencing of CD38 antibodies in RRMM. Mixing foundational evidence and case-based teaching, the experts provide guidance on how to sequence CD38 options based on prior lines of therapy, high-risk features, and comorbidities, while addressing dosing, scheduling, and safety considerations associated with CD38 platforms. Watch this CME/MOC/NCPD/IPCE activity today and become part of the A-team against RRMM in your community!
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, allied health professionals, nurses, and other clinicians involved in the care of patients with multiple myeloma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the latest clinical evidence supporting the use of CD38-based platforms in RRMM
- Implement team-based strategies for sequencing CD38 platforms in RRMM based on prior lines of therapy, patient characteristics, comorbidities, and other clinically-relevant factors
- Develop collaborative strategies to address issues such as dosing/scheduling and safety considerations associated with the use of CD38 platforms in RRMM
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Thomas G. Martin, III, MD
Interim Chief, Division of Hematology/Oncology
Director, Adult Blood and Marrow Transplantation Program
Professor of Clinical Medicine
UCSF Helen Diller Family Comprehensive Cancer Center
The University of California, San Francisco
San Francisco, California
Thomas G. Martin, III, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for GlaxoSmithKline and Pfizer.
Grant/Research Support from Bristol Myers Squibb; Janssen
Pharmaceuticals, Inc.; and Sanofi.
Faculty/Planner
Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO
Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio
Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for GlaxoSmithKline; Janssen
Pharmaceuticals, Inc.; Karyopharm Therapeutics; Pfizer; and Sanofi.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Sanofi.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on November 29, 2024; credit is no longer available.
The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enhancing Outcomes With Potent CD38 Antibody Platforms
Media: Enduring Material
Activity Release Date: November 30, 2023
Activity Expiration Date: November 29, 2024
Time to Complete Activity: 60 minutes
Activity Description
Although innovative therapeutics have led to better overall outcomes, multiple myeloma (MM) remains an incurable disease that presents a range of challenges, particularly in relapsed/refractory (RR) settings. In this educational activity, PeerView partners with the HealthTree Foundation for Multiple Myeloma to address these challenges by bringing together MM experts to demonstrate how the healthcare team can enhance care through the judicious selection and sequencing of CD38 antibodies in RRMM. Mixing foundational evidence and case-based teaching, the experts provide guidance on how to sequence CD38 options based on prior lines of therapy, high-risk features, and comorbidities, while addressing dosing, scheduling, and safety considerations associated with CD38 platforms. Watch this CME/MOC/NCPD/IPCE activity today and become part of the A-team against RRMM in your community!
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, allied health professionals, nurses, and other clinicians involved in the care of patients with multiple myeloma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the latest clinical evidence supporting the use of CD38-based platforms in RRMM
- Implement team-based strategies for sequencing CD38 platforms in RRMM based on prior lines of therapy, patient characteristics, comorbidities, and other clinically-relevant factors
- Develop collaborative strategies to address issues such as dosing/scheduling and safety considerations associated with the use of CD38 platforms in RRMM
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Thomas G. Martin, III, MD
Interim Chief, Division of Hematology/Oncology
Director, Adult Blood and Marrow Transplantation Program
Professor of Clinical Medicine
UCSF Helen Diller Family Comprehensive Cancer Center
The University of California, San Francisco
San Francisco, California
Thomas G. Martin, III, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for GlaxoSmithKline and Pfizer.
Grant/Research Support from Bristol Myers Squibb; Janssen
Pharmaceuticals, Inc.; and Sanofi.
Faculty/Planner
Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO
Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio
Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for GlaxoSmithKline; Janssen
Pharmaceuticals, Inc.; Karyopharm Therapeutics; Pfizer; and Sanofi.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Sanofi.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care
StartThis activity expired on November 27, 2024; credit is no longer available.
Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care
Expert commentary is based on data presented at the European Society for
Medical Oncology (ESMO) Congress 2023.
PeerView is an independent publisher of conference news and medical education
programs.
Media: Enduring Material
Activity Release Date: November 28, 2023
Activity Expiration Date: November 27, 2024
Time to Complete Activity: 45 minutes
Activity Description
Emerging evidence supporting modern targeted strategies for the management
of biliary tract cancers (BTC) and gastroesophageal adenocarcinoma (GEA) has
led to the development of several agents to personalize therapy for patients
with HER2-expressing malignancies.
In collaboration with the Cholangiocarcinoma Foundation, this activity will
provide the latest updates on evolving, evidence-based practice standards for
HER2-targeting agents, including emerging data arising from the 2023 ESMO
Congress. Through a conversational exchange of ideas combined with
compelling, case-based instruction, experts will engage in discussions of
real-world patient scenarios to illustrate best practices for the management
of HER2-expressing BTC and GEA, including overcoming barriers associated with
baseline molecular testing for personalized therapy selection.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, gastrointestinal oncologists, hepatobiliary surgeons, hepatologists, gastroenterologists, physician assistants, nurse practitioners, pharmacists, and other healthcare professionals involved in the care of patients with GI cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize current evidence supporting targeted agents for the management of HER2-positive GI cancers, including safety/efficacy profiles, dosing considerations, and their role in current treatment protocols
- Develop individualized treatment plans based on molecular findings, current and emerging clinical evidence, and guideline recommendations when managing patients with HER2-expressing BTC and GEA
- Integrate team-based strategies to prevent and manage well-documented adverse events associated with HER2-targeting therapies when managing patients with BTC and GEA
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Josep Tabernero, MD, PhD
Head, Medical Oncology Department, Vall d’Hebron University Hospital
(HUVH)
Director, Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain
Josep Tabernero, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim
International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai
Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd;
Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly;
Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.;
NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc;
Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S;
Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda
Oncology, ; and TOLREMO Therapeutics AG.
Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics,
Pangaea Oncology and 1TRIALSP.
Co-Chair/Planner
Shubham Pant, MD
Professor
Department of Gastrointestinal Medical Oncology
Department of Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Houston, Texas
Shubham Pant, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer
Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.;
Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and
Zymeworks Inc.
Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus
Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim
International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering
Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly;
Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals
Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All
goes to Institution.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-072-H01-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 11/27/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on November 27, 2024; credit is no longer available.
Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care
Expert commentary is based on data presented at the European Society for
Medical Oncology (ESMO) Congress 2023.
PeerView is an independent publisher of conference news and medical education
programs.
Media: Enduring Material
Activity Release Date: November 28, 2023
Activity Expiration Date: November 27, 2024
Time to Complete Activity: 45 minutes
Activity Description
Emerging evidence supporting modern targeted strategies for the management
of biliary tract cancers (BTC) and gastroesophageal adenocarcinoma (GEA) has
led to the development of several agents to personalize therapy for patients
with HER2-expressing malignancies.
In collaboration with the Cholangiocarcinoma Foundation, this activity will
provide the latest updates on evolving, evidence-based practice standards for
HER2-targeting agents, including emerging data arising from the 2023 ESMO
Congress. Through a conversational exchange of ideas combined with
compelling, case-based instruction, experts will engage in discussions of
real-world patient scenarios to illustrate best practices for the management
of HER2-expressing BTC and GEA, including overcoming barriers associated with
baseline molecular testing for personalized therapy selection.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, gastrointestinal oncologists, hepatobiliary surgeons, hepatologists, gastroenterologists, physician assistants, nurse practitioners, pharmacists, and other healthcare professionals involved in the care of patients with GI cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize current evidence supporting targeted agents for the management of HER2-positive GI cancers, including safety/efficacy profiles, dosing considerations, and their role in current treatment protocols
- Develop individualized treatment plans based on molecular findings, current and emerging clinical evidence, and guideline recommendations when managing patients with HER2-expressing BTC and GEA
- Integrate team-based strategies to prevent and manage well-documented adverse events associated with HER2-targeting therapies when managing patients with BTC and GEA
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Josep Tabernero, MD, PhD
Head, Medical Oncology Department, Vall d’Hebron University Hospital
(HUVH)
Director, Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain
Josep Tabernero, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim
International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai
Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd;
Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly;
Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.;
NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc;
Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S;
Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda
Oncology, ; and TOLREMO Therapeutics AG.
Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics,
Pangaea Oncology and 1TRIALSP.
Co-Chair/Planner
Shubham Pant, MD
Professor
Department of Gastrointestinal Medical Oncology
Department of Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Houston, Texas
Shubham Pant, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer
Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.;
Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and
Zymeworks Inc.
Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus
Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim
International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering
Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly;
Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals
Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All
goes to Institution.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-072-H01-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 11/27/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView